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 ABSTRACT 
Nazanin Navabi 
Department of Medical Biochemistry and Cell biology, Institute of Biomedicine, 
Sahlgrenska Academy at University of Gothenburg 
 
The gastrointestinal tract is protected by a continuously secreted mucus layer formed 
by mucin glycoproteins. The mucus layer and mucins change dynamically during 
infection. The main focus of this thesis was to investigate the changes in mucin and 
the mucus layer in the gastrointestinal tract during infection with the gastrointestinal 
pathogens C. rodentium (a mouse model for intestinal A/E pathogens), ETEC and 
H.pylori. To be able to compare the results from murine studies to the effect of 
infection in humans, we needed an in vitro mucosal surface to most resemble the in 
vivo environment. Therefore, we developed a method of culture to create an in vitro 
model suitable for studies of host-pathogen interactions at the mucosal surface that 
caused the cells to polarize, form functional tight junctions, a three-dimensional 
architecture resembling colonic crypts, and produce an adherent mucus layer.  
 
We	investigated	the	effect	of	infection	with	H.	pylori	on	mucin	synthesis	in	vivo.	
The	 results	 of	 our	 non‐radioactive	 “pulse”	 experiments	 showed	 H.	 pylori	
colonization	in	the	mucus	niche	of	the	murine	stomach	leads	to	decreased	mucin	
production	and	secretion	rate.	H.	pylori	infection	also	decreased	levels	of	MUC1	
in	the	mucosa.	
The effect of C. rodentium infection on the distinct aspects of the mucus layer and 
mucins was also investigated during this work. Our results in the WT mice 
demonstrated mucus transcription and secretion are dynamically altered in response 
to the infection. Furthermore, the clearance of the infection coincides with the 
reformation of the organized inner mucus layer and an increased mucus thickness, 
which corresponded with altered ion channel activities.  
 
To examine the effect of the cytokine environment on the changes of mucin and 
mucus layer, we infected WT and IFN-γ-/- mice with C. rodentium that resulted in a 
vast enhancement of mucus thickness in the IFN-γ-/- mice compared to the WT 
animals. The effect of individual cytokines was further studied using our in vitro 
model with and without infection with C. rodentium/ETEC. The outcome 
demonstrated that changes in the goblet cells, mucin and mucus layer during 
infection is dependent on the combined impact of the pathogen and cytokines, and 
that the presence of the Th2 cytokines accelerated the process of mucin synthesis.  
Keywords: Mucin, gastrointestinal cell lines, mucus layer, secreted mucin, cell surface 
mucin, H. pylori, C. rodentium, ETEC, mucin secretion, goblet cells 
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ABBREVIATIONS 
A/E Attaching and effacing 
C. rodentium Citrobacter rodentium 
Cag A Cytotoxin-assocciated gene A 
cAMP Cyclic AMP 
CCh Charbacol 
Cp Membrane capacitance 
CT Cholera toxin 
E. coli Escherichia coli 
EHEC Enterohemorrhagic Escherichia coli 
EPEC Enteropathogenic Escherichia coli 
ETEC Enterotoxigenic Escherichia coli 
GI Gastrointestinal 
H. pylori Helicobacter pylori 
H. pylori SS1 H. pylori (Sydney strain) 
IFN Interferon 
IFN-γ-/- Interferon deficient  
IL Interleukin 
LEE Locus of enterocyte 
Muc2-/- MUC2 deficient  
PD                Transepithelial potential 
Rp Epithelial resistance 
TNF Tumor necrosis factor 
Th T helper cell 
Vac A Vacuolating cytotoxin 
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INTRODUCTION 
Background 
The mucosal tissues of the gastrointestinal tract present an enormous surface area to 
the exterior environment, and are frequently challenged by pathogens and antigens 
contained in food and water. In fact, mucosal tissues represent the site of infection or 
route of access for the majority of bacteria that cause human disease and are major 
sources of morbidity and mortality. One very prevalent gastrointestinal infection is 
diarrheal disease, which is the third most common cause of mortality from infectious 
diseases worldwide. Gastrointestinal infection is also associated with chronic 
diseases, such as Helicobacter pylori infection, which can lead to gastric cancer. Half 
the world population is estimated to be infected with H. pylori [1]. 
The mucus layer that covers the mucosal tissue of the gastrointestinal tract is the first 
barrier that encounters the pathogens, and it is continually washing the mucosal 
surfaces and removing trapped bacteria. However, there are studies that indicate 
different bacterial species have gained the ability to alter the features and dynamics 
of mucins, which are the main component of mucus, and colonize the mucosal 
surface. At present, the mechanism of interaction between pathogens and mucus 
during infection is not completely characterized. Since the bacterial penetration into 
the mucus layer and colonization is the first step in the establishment of infectious 
diseases, a characterization of the regulatory networks that interface with mucin 
producing cells may have broad biomedical application.   
The gastrointestinal tract 
The gastrointestinal (GI) tract is a system of organs that facilitates the ingestion, 
digestion, and absorption of food with the subsequent defecation of waste [1]. It 
consists of the oral cavity, esophagus, stomach, small intestine, large intestine, and 
the anus. The GI tract is divided into four concentric layers: mucosa, submucosa, 
muscularis externa, and adventitia or serosa [2]. The mucosa is the innermost layer 
surrounding the lumen and consists of epithelium, lamina propria, and muscularis. 
The self-renewing epithelial cells of the mucosal surface secrete mucins, enzymes, 
and other biochemicals that either aid in digestion or protect the mucosa [2]. The 
gastric epithelium contains multiple cell lineages and is organized into four distinct 
zones, surface/pit foveolus, isthmus, neck and base, and its mucin producing cells 
consist of surface, neck and pit cells [1]. The intestinal epithelium mainly consists of 
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four different cell types: absorptive (enterocytes), enteroendocrine, mucosecreting 
(goblet cells) and Paneth cells [2]. 
The Mucosal Surface 
The mucosal surface of the GI tract is the first barrier that protects this organ against 
potential insults from the environment. The importance of the defense mechanism of 
this surface is highlighted by the fact that gastrointestinal infections kill around 2.2 
million people globally each year [2]. The front line of this protective barrier is the 
mucus layer that covers the epithelial cells and acts as a lubricant, facilitate 
absorption of nutrients, provide a favorable environment for commensal 
microorganisms, occlude microbial invasion and provide a matrix for a broad 
spectrum of antimicrobial molecules [3,4]. The thickness of the mucus layer varies 
throughout the GI tract and is thickest in the colon and stomach and thinnest in the 
jejunum [3,4]. The continuous mucus layer in the stomach and colon consists of two 
layers: an adherent inner layer that covers the mucosa, and a thicker loose layer. The 
inner layer of the colon is densely packed, and has a compact and stratified 
appearance. The small pore size of this layer can physically prevent bacterial 
penetration; therefore, this inner layer is normally devoid of bacteria [5]. In contrast, 
the inner layer of the stomach is fully penetrable by beads the size of bacteria [6]. 
Furthermore, it maintains a pH gradient ranging from 2 at the lumen and 7 at the 
epithelial surface [7]. The inner layer is well organized with a laminated appearance, 
and converts into the outer layer. The outermost loosely adherent mucus layer is 
continually removed by movement of the luminal contents and renewed, which 
results in clearing trapped material. In contrast to stomach and colon, the small 
intestine contains one loose layer of mucus, which is permeable to bacteria [5]. 
Underneath the mucus layer, a second line of defense is comprised by the epithelial 
glycocalyx, which is partially integrated with the overlying mucus gel. The 
glycocalyx is an extracellular zone on the apical surface of mucosal epithelial cells, 
composed of proteoglycans, glycolipids and transmembrane glycoproteins  including 
cell-surface mucins [8]. Some definitions of glycocalyx include the mucus layer, 
however, in this thesis we refer to glycocalyx and the mucus layer as separate 
entities. The glycocalyx also varies in thickness depending on body location [8]. 
 Mucins 
The main components of the mucus layer are mucin glycoproteins produced by 
epithelial mucus-producing cells, including goblet cells. Mucins are also a major part 
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of the glycocalyx. They are highly glycosylated glycoproteins consisting of a protein 
backbone (apomucin) with a few N-glycan chains and large number of relatively 
short oligosaccharides side chains attached to serine (Ser) or threonine (Thr) residues 
via O-glycosidic linkages [9]. Mucin domains are built on a protein core that is rich 
in the amino acids proline, serine and threonine (called PTS sequences). There is 
genetic polymorphism in these sequences which is known as “variable number of 
tandem repeats” (VNTR), although as lately shown, this is not always the case [10]. 
The oligosaccharides chains that are clustered into the highly glycosylated domains 
are the cause of the “bottle brush” appearance of mucins. These structures are 
important in covering the protein backbone and protect the mucins from digestion 
and bacterial proteases [11]. The chains are terminated by fucose, galactose, GalNAc 
or sialic acid residue in the peripheral region that can form histo-blood-group 
antigens such as A, B, H, Lewis a (Lea), Lewis b (Leb), Lewis x (Lex), Lewis y (Ley), 
sialyl-Lea and sialyl-Lex structures [12]. The N-linked oligosaccharides are associated 
with folding and oligomerization or surface localization [13,14]. In general, mucins 
are divided into: secreted (gel-forming), secreted (non-gel forming) and cell-surface 
mucins [15].  
Secreted mucins 
The secreted mucins are gel-forming except for MUC7 (found in saliva), and are 
responsible for the viscous property of the mucus layer. In the stomach, MUC5AC 
produced by surface epithelial cells and MUC6 secreted from sub-mucosal glands are 
the major secreted mucins, while intestinal goblet cells secret MUC2, the 
predominant mucin in the intestine. Genes of these secreted gel-forming mucins are 
clustered on chromosome 11p15 and share some sequence homology [16]. The core 
proteins of secreted mucins are very large (typically more than 5,000 amino acids), 
and their ability to form mucin-type gels results from polymerization of their C- and 
N-terminal regions that contain conserved cysteine-rich von Willebrand D domains 
[17].  
Synthesis of secreted mucin  
The assembly pathway of mucin synthesis in the highly polarized mucin producing 
cells start at the endoplasmic reticulum (ER), in the basal cytoplasm of these cells. 
The protein backbones of the mucins are synthesized on polyribosomes, located at 
the cytoplasmic face of the ER, and co-transitionally translocated across the 
membrane into the lumen of the ER. During this translocation, N-glycosylation of 
mucin monomers occurs in the polypeptide chain followed by intramolecular 
disulfide-stabilized folding. Intermolecular disulfide bonds between the monomers, 
mediated by cysteine residues in the C-terminus (cysteine knot domain), results in 
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non-O-glycosylated dimmers. Correct folding of the protein is essential at this point 
to allow the translocation of mucin dimers to the Golgi complex and prevent their 
aggregation in the ER [18-20]. This translocation occurs by vesicular transport of the 
mucin to the Golgi where O-glycan chains are attached to the mucin by 
glycosyltransferases [15]. The O-glycan elongation is dependent on the initial 
addition of GalNAc to serine and threonine residues, and this key step of the process 
is catalyzed by polypeptide-GalNAc transferases. After glycosylation, while 
transiting through the trans-Golgi network, the dimers are further polymerized [21], 
and are packed into secretory granules and stored [22,23]. The exact mechanism of 
this packaging into a highly condensed and dehydrated state in the secretory granules 
is not completely clear. However, pH and Ca2+ ions have been implicated as essential 
components; calcium ions being particularly important for shielding the negatively 
charged sugars [24-26]. A summary of the process of mucin synthesis is shown in the 
schematic picture in Figure 1A.  
 
 
 
 
 
 
 
 
Figure 1. Schematic of cell-surface and secreted mucins biosynthesis in the 
epithelial cells. The schematic shows synthesis of A) secreted mucin in goblet cells, 
B) cell-surface mucins in epithelial cells. In the ER, secreted mucins are N-
glycosylated and dimerize via their C-terminal domains. Cell-surface mucins are 
cleaved into two subunits in the endoplasmic reticulum, inserted into the membrane 
and N-glycosylated. Both cell surface and secreted mucins are O-glycosylated in the 
Golgi. Following completion of O-glycosylation, the dimers of the secreted mucins 
undergo N-terminal oligomerization and are packed into granules for secretion. 
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Ion channels and mucin release 
Post-secretion, the mucins mature by quick release and hydration that result in more 
than a 1000 fold expansion [27]. Bicarbonate ions in the extracellular milieu are 
suggested to be the factor that is involved in removing Ca2+ ion and increasing pH 
[28]. The importance of Ca2+ ions in the release of mucin is supported by the studies 
on MUC2 [26,27,29]. Bicarbonate is exchanged for chloride or short-chain fatty 
acids [30] and its secretion is modulated by a variety of secretagogues that can 
induce cyclic AMP (cAMP) or Ca2+ dependent pathways. The cAMP dependent 
secretion opens cAMP gated K+ channels, activates Na+/K+/Cl- co-transporters [31], 
and transports bicarbonate over the basolateral membrane by sodium-bicarbonate co-
transporters (i.e. NBCel and NBCn1) [32]. The transporter for the Ca2+ dependent 
pathway relies on the bicarbonate in combination with Na+/H+ exchange [33] that 
results in increased levels of Ca2+ and activation of protein kinase C [34]. The exit of 
bicarbonate over the apical membrane has also been related to two pathways; the 
cystic fibrosis transmembrane conductance regulator (CFTR) channel on enterocytes, 
and Bestrophin-2 (Best2) (a Ca2+-activated Cl channels) expressed by goblet cells 
[35] which are respectively activated by cAMP and Ca2+ pathways respectively. The 
activation of each cascade is dependent on the secretogogues.  
Cell-surface mucins 
The cell-surface mucins represent major components of the glycocalyx, and are 
expressed on the apical membrane of all mucosal epithelial cells. MUC1 is the main 
cell-surface mucin in the stomach, whereas MUC3A, MUC3B, MUC4, MUC12, 
MUC13, MUC15 and MUC17 are those present in the intestine [8]. Many 
gastrointestinal cells express multiple members of the cell-surface family, and there 
is a variation in the relative expression of these mucins between distinct cell types 
and different regions of the GI tract [36]. An integral transmembrane domain binds 
these mucins to cells, and their relatively short cytoplasmic tails associate with 
cytoskeletal elements, cytosolic adaptor proteins and/or participate in signal 
transduction [37]. Centrally located PTS regions are the characteristic feature of all 
mucins, differentiating them from other membrane-bound glycoproteins. The cell-
surface mucins also have SEA domain  [38] and epidermal growth factor domains 
[39] that are involved in cleavage and signaling pathway respectively [40,41]. The 
EGF-like domains are postulated to function by allowing cell-surface mucins to 
interact with members of the EGF receptor family, which are likely involved in 
regulation or signaling of growth, motility, differentiation, and inflammation [40,41]. 
Specific proteolytic cleavage occurs within the SEA domain of the extracellular 
juxtamembrane part of the cell-surface mucins during the intracellular post 
translational process for the part of the protein that is destined to be expressed on the 
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extracellular surface [42]. The two subunits created by this cleavage remain non-
covalently linked during cellular transport through the endoplasmic reticulum, the 
Golgi complex and at the cell surface. These subunits facilitate the release of the 
extracellular domain at the cell surface in response to alterations in pH, ionic 
concentration, hydration and/or specific proteases mediators. The mechanism that 
controls this release has not been clearly elucidated [43]. A summary of the process 
of cell-surface mucins synthesis is shown in the schematic in Figure 1B.  
Mucin dynamics 
The mucosal barrier is not a static surface, as continuous mucus production and 
secretion are required to keep the homeostasis of this surface. The secretion of 
mucins is divided into two forms: constitutive or baseline and stimulated or 
accelerated secretion in response to external stimuli. The constitutive continuous 
secretion is necessary to maintain the thickness of mucus lost in the movement of 
luminal contents and/or degraded by luminal bacteria. The secretion of mucin is 
highly regulated by the luminal microenvironment, neural, endocrine and immune 
factors, and involves the transport of granules via actin remodeling, binding to the 
membrane and exocytosis [44,45].  
Accelerated secretion is a receptor-mediated event, in which the intracellular Ca2+ ion 
level has been shown to act as the regulator [46,47]. Exposure of mucin producing 
cells to potent secretagogues induces a rapid increase in the release of mucin 
granules. The discharge occurs via fusion of the centrally stored mucin granules with 
the plasma membrane followed by the release of their contents into the lumen [48]. 
The process is continued by the fusion of adjacent vesicles to the membrane of 
previously released granules, and can result in release of entire mucin granule content 
within a minute [48]. Accelerated secretion occurs in response to a range of 
environmental stimuli including microbial components, inflammatory cytokines, 
prostaglandins, cholinergic stimuli, lipopolysaccharide, bile salts, nucleotides, nitric 
oxide, vasoactive intestinal peptide, neutrophil elastase, and components of the 
immune system [49-58]. The effect of microbial components on accelerated secretion 
has been detected in both in vitro and in vivo studies. For example, the cholera toxin 
(CT) from Vibrio cholerae, was shown to trigger a massive mucin release via a 
cAMP-dependent mechanism from cultured intestinal HT29 goblet cells [59]. In vivo 
studies in rabbit, suggested that the acceleration of mucin secretion by CT is an 
indirect mechanism that might be mediated by mucosal nerve cells or other cell types 
[60,61]. Moreover, infection of a gerbil model of amebic colitis with the enteric 
protozoan parasite Entamoeba histolytica resulted in depletion of stored mucin from 
the goblet cells that has been related to the effect of parasite-derived secretagogues 
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[62,63]. Bioactive factors of the immune system are other important stimulators of 
accelerated mucin secretion [45].  
The mucosal immune system and mucin secretion 
The mucosal immune system of the GI tract forms one of the largest immunological 
organs with a dual function: to protect the GI tract from invading pathogens and to 
tolerate both ingested food antigens and the commensal microbiota. In addition to 
mucins, epithelial cells secrete a number of factors that contribute to barrier function, 
including antimicrobial peptides, and trefoil factors. The epithelial cells are also 
involved in mediating the innate immune response via their pattern recognition 
receptors, such as Toll-like receptors, which are the nucleotide-binding 
oligomerization domain receptors-like receptor proteins that can identify pathogen-
associated molecular patterns (PAMPs). The outcome of the induction of innate 
immunity is a diverse response that includes the release of anti-microbial peptides 
and cytotoxic molecules, phagocytosis and intracellular killing of microbes and  
complement activation. Furnthermore, release of innate cytokines: interleukin 1 β 
(IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α), and release of 
acute-phase proteins from the liver that assist in pathogen clearance [64]. In addition, 
cell-surface mucins, as shown for MUC1, can modulate the activation of nuclear 
factor-ĸB (NF-ĸB), which is the transcriptional factor involved in the regulation of 
inflammatory signaling [65,66]. Underneath the epithelial layer, are the lamina 
propria, which are populated by immune cells, including mononuclear phagocytes 
(macrophages and dendritic cells) and eosinophils (in normal intestine), antibody-
secreting B cells (mainly secrete IgA) and cytotoxic (CD8+) and helper (CD4+) 
T cells [64,67]. CD4+ T cells can be further subdivided based on their secreted 
cytokines: Th1 that secretes interferon gamma (IFN-γ) and assists in clearing 
intracellular pathogens by activating macrophages; Th2 that secretes interleukin-4 
(IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13), and provides help to B cells 
for antibody production; Th17 secretes interleukin-17 (IL-17), and plays an important 
role in microbial clearance and a destructive role in autoimmunity [49].  
Stimulation of the innate and adaptive immune response, in addition to direct 
regulation of epithelial cells, can affect the secretion rate of mucins and 
differentiation of goblet cells. For example, the stimulation of the human gastric cell 
line with IFN-γ prompted secretion of mucus and expression of MUC6 [68]. IL-4 and 
IL-13 also induced the expression of the transcription factor SPDEF, which regulates 
goblet cell differentiation and expression of genes involved in mucin synthesis and 
secretion [69-73]. The decrease in the total amount of mucins in response to IFN-γ 
and TNF-α was detected in some experiments: simultaneous addition of IFN-γ and 
TNF-α to a monolayer of cultured goblet cell line Cl.16E devoided the cells of mucus 
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granules [74]. Vaccination of mice that induced the IFN-γ secreting cells led to a 
decreased level of Alcain blue/PAS staining (mucins) in the airway epithelium of 
mice with allergic inflammation [75]. However, an increase in mRNA of secreated 
mucins was detected in response to different cytokines. For example, in vitro 
stimulation of dog bronchoalveolar lavage cells with IL-9 increased MUC5AC gene 
expression [76]. TNF-α and IL-6 stimulated mucin secretion by cultured colonic cells 
and increased the gene expression of MUC2, MUC5AC, MUC5B, and MUC6 [50]. 
IL-1 stimulation of mucin release has been detected in rat colon [77], and the 
addition of this cytokine to cultured colonic LS180 cells increased the mRNA levels 
of MUC2 and MUC5AC [50]. IL-13 produced in response to murine intestinal 
parasitic infections stimulated goblet cell hyperplasia and increased Muc2 and Muc3 
mRNA levels [78,79]. The dose dependent effect of some cytokines on the changes 
of mucins have also been reported: in vitro experiments on HT29-Cl.16E colonic 
cells indicated a dose-dependent release of mucin in response to IL-1 [56]. In 
addition, IFN-γ increased mucin synthesis (measured by radioactive labeled secreted 
material) in HT29 and LIM-6 intestinal cell lines in a dose-dependent manner, but 
had no effect on LS174T and Caco2 cell [80].  
 
 
 
 
 
 
 
Figure 2. Role of mucin in defense against GI pathogens. Invasion of epithelial 
surface by enteric pathogens can result in: A) discharge of mucin in direct response 
to pathogen, B) shedding of cell-surface mucins and clearance of the cell surface 
from bacteria, C) activation of immune responses that stimulates mucin release. 
Mucins and pathogenic invasion 
The direct involvement of mucins in preventing pathogenic invasion has been proven 
by the outcome of studies on mice with a deficiency in secreted or cell-surface 
mucins. Infection with Citrobacter rodentium (C. rodentium, an infectious agent 
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providing a self-limiting mouse model for attaching and effacing Escherichia coli) in 
Muc2 deficient mice (Muc2-/-) developed severe, life-threatening disease [81]. The 
Muc2-/- mice also demonstrated a delay in clearance of the nematode parasite 
Trichuris muris [82]. Furthermore, mice deficient in Muc1 are more susceptible to 
infection with the gastric pathogen Helicobacter pylori (H. pylori) [66,83] and the 
intestinal pathogen Campylobacter jejuni (C. jejuni) [84]. Despite the general 
acknowledgment of the importance of mucins in the defense against pathogens, the 
detailed mechanism of this defense is not fully understood.  
Enteric pathogens have developed a range of strategies to subvert and avoid the 
mucosal layers and reach the underlying epithelial surface, where they can initiate 
disease. Flagella are a common feature that appears to assist bacterial penetration into 
the viscous mucus layer [85-89]. In addition, different mechanisms are used by 
pathogens to alter the mucus layer to facilitate their motility. Some pathogens 
increase the pH of their surrounding environment to decrease the mucus 
viscoelasticity [90], while others disassemble the oligomerized mucin 
macromolecules by proteolytic cleavage and dissolving the mucus gel [91]. In turn, 
the host response to pathogens includes changes in mucin production, as well as 
modification of the constituents and biophysical properties of mucus [45]. For 
example, based on immunohistological staining, infection with C. rodentium (in 
mouse), Salmonella St Paul, C. jejuni and Clostridium difficile (in human) increased 
the quantity of Muc1/MUC1 in the colon [36]. Furthermore, long term infection with 
H. pylori changed the mucin glycoslation with a decrease in fucosylation and 
increase in sialylation [92]. A massive discharge of mucin in response to microbial 
products has been detected in a range of studies [8,45] (Figure 2A). For example, in 
vitro treatment of cultured intestinal goblet cells with LPS from  Escherichia coli  (E. 
coli), demonstrated up-regulation of MUC5AC and MUC5B mRNA in these cells 
[93]. In addition, LPS from Pseudomonas aeruginosa resulted in an increase in gene 
expression of MUC5AC and PAS/Alcian blue staining in mouse tracheal epithelial 
cells [94]. An increase in the level of MUC5AC mRNA in mucoepidermoid cells of 
the lung has also been detected in response to Pseudomonas aeruginosa flagellin in 
parallel to interleukin-8 (IL-8) secretion [95]. Addition of culture supernatant from 
Fusobacterium nucleatum to human bronchial epithelial cells up-regulated MUC5AC 
mRNA [96]. 
The pathogens that do penetrate the inner mucus layer are likely to interact with cell-
surface mucins, which restrict their binding to other glycoproteins and neutralize 
these pathogens. Subsequent to this binding, the cell-surface mucin could shed and 
act as a decoy to limit the adhesion of pathogens to the epithelial cells [83] (Figure 
2B). In addition, there is emerging evidence that indicates adhesion of pathogens to 
cell surface mucins stimulates the inflammatory signaling cascade of epithelial cells 
[97] (Figure 2C). 
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Helicobacter pylori 
H. pylori is a micro-aerobic, Gram-negative, helical rod-shaped bacterium that 
colonizes the gastric mucosa of approximately half of the world’s population [98]. 
Although most people infected with H. pylori are asymptomatic, this bacterium has 
been recognized as the primary cause of several gastric diseases, including chronic 
gastritis, peptic ulcer disease and gastric mucosa lymphoid tissue lymphoma, and 
also as the main risk factor for gastric cancer [99-102]. The clinical outcomes of 
H. pylori infections are determined by the host–pathogen interactions. Parameters 
such as the bacterial genotype, environmental determinants and host genetics are 
important for the progression of disease [103]. H. pylori colonization usually occurs 
during childhood, and once established the bacteria can remain in the gastric mucosa 
for life [104]. H. pylori isolates have diverse genome sequence and pathogenicity, 
and different factors are involved in their pathogenesis. The virulence factors such as 
urease, flagella, adhesins, and toxin delivery systems seem to be crucial for H. pylori 
colonization and establishment of infection in the gastric mucosa. To facilitate the 
colonization of the gastric mucosa, the urease enzyme of H. pylori converts urea to 
ammonia ions, and elevates the pH of the microenvironment around the bacteria, 
which protects it from the acidic gastric lumen [105,106]. The increase in pH also 
facilitates bacterial penetration into the mucus layer by transforming the viscoelastic 
mucus gel (at low pH), that effectively traps the bacteria, to a viscoelastic solution 
[107]. In the suitable environment provided by urease, flagella mediate the motility 
of H. pylori; it may enable the bacteria to penetrate the mucus gel and to remain near 
the epithelial layer despite the rapid turnover of mucus layers. The movement of H. 
pylori is dependent on a unipolar bundle of two to six sheathing flagella, and this 
sheathing is also believed to protect the bacteria from the acidic environment in the 
stomach [108]. An additional important factor in the motility of H. pylori is its 
helical rod shape, which may enable the bacterium to swim faster in the mucus layer 
[109]. After penetration, H. pylori persists in the stomach, possibly by using several 
outer membrane proteins, which adhere to the corresponding receptors on the host 
gastric epithelium. A number of adhesins have been identified on H. pylori such as 
surface-located heat shock protein [110], HopZ [111], AlpA/AlpB [112] and OipA 
[113]. However, the most studied adhesins are the blood group antigen binding 
adhesin (BabA), sialic acid binding adhesin (SabA), cytotoxin-associated gene L 
(CagL) that respectively binds to fucosylated structures such as lewis b antigen (Leb), 
sialyl-Lex and integrin [114-117]. BabA can also act as a mediator for H. pylori 
binding to MUC5AC, even in non-secretors or those without Leb [118]. Following 
colonization, H. pylori delivers toxins into the epithelium, mediated through the 
vacuolating cytotoxin (VacA) and cytotoxin-associated gene A (CagA). The VacA 
toxin has pore-forming activity and induces vacuolation and apoptosis in epithelial 
cells [119], as well as inhibition of T lymphocyte proliferation [120,121]. CagA is a 
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member of the cytotoxin-associated gene pathogenicity island, which expresses a 
type IV secretion system and induces a pro-inflammatory response and multiple 
cytoskeletal and gene regulatory effects on gastric epithelial cells [122].   
H. pylori invasion can be recognized by a variety of putative pathogen recognition 
molecules in the host, which are capable of regulating the innate and adaptive 
immune responses through recognition of conserved microbial components. The 
result is the production of inflammatory cytokines such as interleukin-8 (IL -8), 
interleukin-12 (IL-12), IL-6, IL-1β, interleukin-18 (IL-18), interleukin-10 (IL-10), 
and TNF-α [123-125]. Long term colonization of the gastric mucosa by H. pylori 
induces the adaptive immune system to elicit Th1 and Th17 cell responses, which 
results in elevated levels of the cytokines IFN-γ and IL-17 [126,127]. In general, 
despite the effort of the host immune system to eradicate H. pylori from the mucosal 
surface, this bacterium has evolved defense mechanisms which secure its long term 
colonization. 
Gastric mucin and H. pylori 
Several studies have demonstrated that H. pylori bind to the MUC5AC and MUC1 
mucins [128-130]. Furthermore, MUC1 can block the binding of H. pylori to the 
epithelial surface, though the mechanisms are different between strains with BabA 
and SabA and the strains without these adhesins. Infection of cultured gastric cells 
with H. pylori strains expressing these adhesins causes the shedding of MUC1 from 
the cell surface, coats the bacterium and acts as a decoy to limit binding to the 
epithelial layer [83]. Conversely, in the strains which lack BabA and SabA, the 
mucin blocks binding of the bacterium to the cell surface by steric hindrance [83]. 
Mucins can also influence the proliferation, gene expression, and virulence of H. 
pylori [131].  
In addition, there appear to be changes of the mucin expression during infection 
based on the outcome of several studies, although there is some controversy about 
the decrease of MUC5AC levels. The immunohistochemical studies on human 
biopsy specimens from H. pylori infected individuals detected no difference in 
MUC5AC protein levels [132-134], while another study demonstrated a reduction of 
both MUC5AC and MUC5AC expressing cells [135]. Furthermore, an in vitro study 
using the gastric cancer cell line KATO-II infected with H. pylori found that mucin 
synthesis decreased upon infection [136,137]. MUC6, which is normally produced by 
gastric gland mucous cells, have been reported to be expressed in surface mucous 
cells in H. pylori infected patients [134]. In human biopsy samples the thickness of 
the adherent mucus layer remained intact in infected patients [138], whereas H. 
pylori infection in mice decreased the thickness of the adherent mucus layer [139]. 
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Infection with H. pylori can also lead to intestinal metaplasia, with the stomach 
mucus developing characteristics of intestinal mucus [140]. MUC6, which is 
normally produced by gastric gland mucous cells, have been reported to be expressed 
in surface mucous cells in H. pylori infected patients [134]. MUC6 from one patient 
could inhibit proliferation of H. pylori in a dose-dependent manner, and thereby act 
as a natural antibiotic, potentially decreasing the bacterial burden [141].  
H. pylori SS1 (Sydney strain) 
To achieve a better understanding of the in vivo mechanism of the H. pylori 
infection, many investigators have chosen to use the mouse as a model. However, 
most of the strains obtained from patients have low colonization kinetics and a weak 
phenotype in mice. In 1997, Lee and colleagues in Australia successfully adapted the 
Sydney strain-1 (SS1) isolates of H. pylori through serial inoculation in the mouse 
stomach [142]. Today, the H. pylori SS1 strain is the most commonly used infecting 
agent for mouse studies, that colonizes, in particular, the C57BL/6 strain for longer 
periods and with a higher number of bacteria compared to other available strains of 
mice [142]. H. pylori SS1 can colonize and produce gastritis in the mouse, although 
the infection with this strain does not exactly mimic human gastritis. Moreover, the 
formation of gastric ulcers and cancer has not been observed in mice during infection 
with the SS1 strain [143]. However, the long-term pathology has more in common 
with human chronic gastritis in comparison to other strains of helicobacter [142]. 
Escherichia coli 
E. coli  a gram-negative, rod-shaped bacterium, is an incredibly adaptable and 
diverse enterobacterial species. E. coli can be subdivided into the intestinal non-
pathogenic (commensal isolates), intestinal pathogenic isolates and extraintestinal 
pathogenic E. coli or ExPEC isolates, based on genome content and phenotypic traits. 
Several intestinal pathogenic subspecies of diarrheagenic E. coli have been 
described: enteroinvasive E. coli(EIEC), cnteroadherent or enteroaggregative 
(EAEC), enterotoxigenic (ETEC), enteropathogenic (EPEC) and enterohaemorrhagic 
(EHEC), based on the clinical syndromes they can cause and their virulence traits 
[144].  
ETEC 
Enterotoxigenic Escherichia coli (ETEC) is one of the six recognized diarrheagenic 
E. coli and the most common cause of diarrhea in children in developing countries, 
and also in travelers in those areas. Approximately, 200 million diarrheal episodes 
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and 380,000 deaths are caused by ETEC annually [145]. The pathogenicity of ETEC 
depends on its colonization and virulence factors. Adherence of ETEC to the 
intestinal mucosa is facilitated by colonization factors (CFs) that are remarkably 
selective for host and tissue. CFA/I and CS1 to CS6 are generally more prevalent 
than other identified CFs in human ETEC [146]. Following colonization, the 
virulence factors of ETEC, which consists of heat-labile enterotoxin (LT) and/or 
heat-stable enterotoxin (ST), stimulates net secretion of ions and water, causing 
watery diarrhea [147]. In addition to these virulence factors, ETEC has evolved other 
mechanisms to overcome the protective effect of the mucus layer to invade the 
epithelial surface. Recent in vitro studies demonstrated the ability of ETEC in 
degrading MUC2, which accelerated toxin access to the enterocyte surface [148,149]. 
In addition, previous studies in pig established binding of the cell-surface mucins 
MUC4, MUC13 and MUC20 to the CFs of porcine ETEC [150-152], which can 
block the binding of CFs to the epithelial surface. An in vitro experiment with 
porcine intestinal cells demonstrated downregulation of expression of MUC4 and 
MUC13 by the colonization factors fimbrial types (F4ab and F4ac respectively) of 
porcine ETEC [153]. In addition, knockdown of MUC13 in the same epithelial cells 
resulted in an increase of ETEC adhesion to the cells [154]. The other aspects of 
immune response to ETEC are mainly mediated through secretory IgA directed 
towards the LT toxin and colonization factors [155]. Stimulation of human T cells 
with LT and CFs results in a Th1/Th17 response [156,157] while intranasal 
immunization in mice was reported to effect a mixed response more directed towards 
a Th2 response [158]. 
Attaching and effacing pathogens 
Enteropathogenic Escherichia coli (EPEC) and Enterohemorrhagic E. coli (EHEC) 
are members of the attaching and effacing (A/E) family of pathogens that induce 
histopathological lesions, termed A/E lesions, on the apical surface of the host 
enterocytes [159]. The A/E lesions are characterized by localized destruction of 
brush-border microvilli and intimate attachment of the bacteria to the plasma 
membrane of the host epithelial cells [160]. EPEC is a cause of gastroenteritis in 
infants while EHEC causes bloody diarrhea in children and the elderly. These 
pathogens are distinct from each other based on production of Shiga toxins by 
EHEC, that cause kidney damage leading to the hemolytic uremic syndrome, a form 
of acute renal failure [161]. The A/E pathogens carry a pathogenicity island, the 
locus of enterocyte effacement (LEE) that encodes gene regulators, the adhesin 
called intimin, a type III secretion system, chaperones, and several secreted proteins, 
including the translocated intimin receptor (TIR) [162]. A variety of effectors are 
shared by all A/E pathogens [163], which subvert different host cell processes, and 
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enable the bacteria to colonize, multiply and cause the disease. The type III secretion 
system which is an injection device (injectisome), transfer bacterial virulence 
proteins directly into host cells [164] using two distinct categories of proteins: the 
translocators that form a pore in the target membrane and the effectors that transport 
through this pore into the host cell [162]. Therefore, the EHEC/EPEC remains mostly 
extracellular in the lumen of the intestine, while T3SS injected effectors access and 
manipulate the intracellular environment of the host cells. The effectors can regulate 
the host cellular functions involved in the immune response, the cytoskeleton 
dynamics and the maintenance of tight junctions.  
Citrobacter rodentium 
C. rodentium is a gram-negative, anaerobic rod which produces transmissible murine 
colonic hyperplasia, characterized by epithelial cell hyperproliferation in the 
descending colon [165]. Infection with C. rodentium in most adult mice is subclinical 
and self-limiting, resulting in slight morbidity or mortality [166]. Oral transmission 
of this bacteria in mice initiates with the passage through the cecum, followed by 
colonization of the colonic epithelium, by formation of A/E lesions [167] equivalent 
to that caused by EPEC and EHEC in human. C. rodentium also possesses a 
homologue of the LEE pathogenicity island as described in EPEC/EHEC. These 
similar traits make C. rodentium a useful model for in vivo studies of the molecular 
basis of LEE-mediated pathogenesis, and the mechanisms underlying mucosal 
responses to infection, especially since EPEC and EHEC do not infect adult mice 
efficiently [168]. 
Host defense against A/E pathogens 
A key step for A/E pathogen to invade the epithelial surface appears to be to 
overcome the barrier produced by the outer and inner mucus layer. Indeed, C. 
rodentium infection of Muc2-/- mice indicated extreme susceptibility to infection, 
induced mortality and disease, as well as faster colonization and higher pathogen 
burdens throughout the course of infection in mice lacking a mucus layer [81]. The 
protective effect of the mucus indicates that the bacterial factors involved in crossing 
this layer are presumably critical for virulence. As C. rodentium is non-motile due to 
the lack of a functional flagellum, the ability of the bacteria to overcome the mucus 
barrier has been speculated to utilize specific mucinases or glycosidases that digest 
mucins [169]. The fact that EHEC has been shown to secrete the metalloprotease 
StcE with apparent mucinase activity [170] suggested that A/E pathogens could 
employ this strategy. Furthermore, in C. rodentium infected WT mice an increase in 
luminal mucus was detected at day six post infection compared to non-infected mice, 
which could indicate that Muc2 promotes host defense by flushing C. rodentium 
Nazanin Navabi 
19 
away from the mucosal surface and out of the colon [81]. In addition to the mucus 
layer, the other components of the host immune response that have been shown to be 
necessary for pathogen clearance, are CD4+ T cells, B cells, mast cells, and 
neutrophils [171-175]. IgG responses are also required, whereas IgA and IgM 
responses are not essential [172]. Infection with A/E pathogens leads to elevated Th1 
and Th17 responses, and mice lacking the cytokines needed for these responses (IFN-
γ, IL-12, IL-17, and IL-22) have increased susceptibility to C. rodentium [176-178]. 
It was also determined that the IFN-γ produced by CD4+ T cells is essential for 
controlling pathology and  bacterial density [179], although mice with a deficiency in 
IFN-γ cytokines are still capable of clearing C. rodentium infection, albeit with a 
longer duration of infection [176].  
 
Mucus and mucins during gastrointestinal infections 
20 
AIMS OF THE PROJECT 
 
General aim 
The overall aim of this thesis was to understand the effect of bacterial infection on 
mucin production and turnover in the gastrointestinal tract. 
Specific aims: 
I. To evaluate the production rate and turnover of mucins in the murine 
gastric mucosa in non-infected mice, and mice with early colonization and 
chronic H. pylori infection.  
 
II. To develop an in vitro model that resembles the mucosal surface of the 
gastrointestinal tract by producing polarized cells, functional tight 
junctions, and a mucus layer.  
 
III. To investigate the mucus and mucin dynamics, as well as goblet cell and 
enterocyte function during infection and clearance in the self-limiting C. 
rodentium infection model.  
 
IV. To define the effect of cytokine environment on changes in the intestinal 
mucus layer during infection with C. rodentium and ETEC. 
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METHODOLOGICAL CONSIDERATIONS 
The methods used in this thesis are described in the attached papers and manuscript. 
Only more detail on the method for preserving the intestinal in vitro model is 
described here.  
 
Carnoy’s fixation and preservation of in vitro mucosal surfaces 
(Paper II and IV) 
Previous work on establishing fixation procedures for preserving an intact mucus 
layer demonstrated the importance of avoiding water in the fixatives [134,180]. 
Carnoy’s fixative with dried methanol as the alcohol component (methanol Carnoy) 
was found to be the most efficient preservative for the mucus. Therefore, in our 
experiments, this fixative was used to preserve the in vitro mucosal surface. To 
minimize damage, the membranes were fixed and paraffinized without removing the 
inserts. To keep the secreted mucus intact two methods were used. One method was 
by making a “sandwich” in which a second membrane that had undergone identical 
treatment was cut out of the insert and flipped on top of the other membrane in a 
manner where the apical surfaces were facing each other. The other method used was 
to cover the apical surface of the in vitro membrane with a thin layer of bovine liver, 
followed by immediate soaking in the methanol Carnoy fixative to reduce the 
possible effect of enzymes from liver on the mucus layer.  
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RESULTS  
Maintenance of gastrointestinal mucosal homeostasis is dependent on the balanced 
and dynamic interactions between mucus layer, intestinal epithelial cells, microbiota, 
and the host immune defense [181-183]. To establish infection, the enteric pathogens 
have to disrupt the gastrointestinal homeostasis and cause a defect in the mucus 
barrier to increase permeability. Penetration of pathogens into the mucus layer leads 
to inflammation and disruption of the gastrointestinal epithelial cells. Currently, the 
focus of many studies is on the understanding of the crosstalk between host mucosal 
defense and pathogens. One of the obstacles in understanding the mechanisms of 
these interactions is that many pathogens are human specific and the animal models, 
although useful, have disadvantages when it comes to relating the results to human 
disease. Therefore, to determine the mechanisms of infection, in vitro models are 
necessary. However, the common in vitro cell cultures are suboptimal, as they are 
often not polarized, lack important components of the glycocalyx, and have very low 
production of secreted mucin. Hence, the first objective of this thesis was to establish 
a cell culture method to create reproducible in vitro mucosal surfaces that better 
mimic the in vivo mucosal surface of the gastrointestinal tract. My thesis was 
originally intended to focus on H. pylori infection. However, despite our effort, none 
of the gastric cell lines tested formed an enhanced mucus layer in response to the 
range of applied culture methods used. Due to the combined lack of a suitable gastric 
in vitro model, technical problems with measuring electrical parameters of the 
murine stomach as well as with preserving the gastric mucus layer intact, we decided 
to also include the intestinal pathogens C. rodentium and ETEC.    
In vitro mucosal surfaces suitable for infection studies, created by 
Semi-wet interface culture (Paper II) 
The major traits for creating in vitro mucosal surfaces suitable for infection studies, 
are the abilities to produce continuous adherent polarized layers with functional tight 
junctions, and a mucus layer. To create this layer, we started with the previously used 
air-liquid interface culture condition that change the airway and rabbit conjunctival 
epithelial cells into polarized cells [184,185], and made a series of modification 
experiments leading to a method of semi-wet interface cultivation with mechanical 
stimulation that provides an environment resembling the gastrointestinal milieu. The 
response of different cell lines to this treatment was diverse, and some of them were 
capable of forming firmly adherent continuous polarized layers, whereas other cell 
lines did not have this ability. Amongst tested intestinal cell lines, Caco-2, T84, 
LS513 and HT29 MTX (-P8 and –E12) were capable of producing adherent 
epithelial layers (Caco-2 and T84 do this also in the absence of this treatment). 
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MKN7 cells were the only gastric cell line that produced an adherent polarized 
epithelial layer in response to the semi-wet interface. The mechanical stimulation had 
a negative effect on the integrity of these cells. The cell lines also varied in mucin 
expression, and none of them produced more than 1% of the amount of the mucins 
that builds up the mucus layer in the in vivo gastrointestinal mucosa [186]. The 
mechanical stimulation and continuous wetting of the apical surface used in our 
culture method, provided a more homogenous surface, stimulated mucus production 
and altered the morphology of the LS513, Caco-2, T84 and especially HT29 MTX (-
P8 and –E12) intestinal cells to a three-dimensional structure with some very shallow 
crypts. The addition of a Notch γ-secretase inhibitor (DAPT), which is known to 
promote goblet cell differentiation [187], as a chemical stimulator enhanced the 
thickness of the mucus layer. In summary, the culture of intestinal cell lines LS513, 
and HT29 MTX-P8 and HT29 MTX-E12 in a semi-wet interface with mechanical 
and chemical stimulation resulted in production of an in vitro mucosal layer with 
considerable resemblance to the in vivo environment. The polarized epithelial 
surfaces covered with a relatively thick mucus layer produced from the HT29 MTX 
(-P8 and –E12) cells, is similar to the environment of the in vivo mucosal surface 
during interaction with pathogens. In addition, the reproducibility of these in vitro 
models, especially HT29 MTX-E12 cells, made them suitable model candidates for 
in vitro infection studies. Therefore, we chose this cell line for our infection studies, 
and from here on we refer to the HT29 MTX-E12 culture in semi-wet interface with 
mechanical and chemical stimulation as in vitro mucosal surfaces. 
Changes in mucus layer, mucins and goblet cells in response to 
infection and cytokines (Paper III and IV) 
Previous studies in the gastrointestinal tract indicated that bacterial infection either 
induces goblet cells and mucin synthesis with frequent secretion, or depletes the 
goblet cells followed by quantitative and qualitative alteration in the mucus layers 
[182,188]. These studies usually focus on a single time point, and the regulatory 
cascade involved in the response mechanism of mucin producing cells to the 
pathogens is poorly defined. The current knowledge envisions two possible 
pathways: direct effects of microbes on goblet cell functions through the local release 
of the microbial components; or changes in goblet cell function in response to host-
derived bioactive factors generated by activated epithelial or underlying immune 
cells after interaction with pathogens [189]. To gain a better understanding of the 
effect of pathogens and the host immune system on changes of the mucus layer, we 
used the self-limiting mouse pathogen C. rodentium infection as a model for A/E 
pathogens. We examined the variation in the number of goblet cell, the amount of 
stored mucin and the thickness of the mucus layer of WT mice (C57BL/6) during 
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different phases of infection, from early infection to the clearance of the pathogen 
(paper III). The results showed a progressive change that already began at early 
colonization (4 days post infection). At this time point the thickness of the adherent 
mucus layer decreased to the lowest level, and there was goblet cell depletion, but the 
engorgement of the mucins inside the goblet cells increased to its highest level. 
During day 10 post infection when the fecal C. rodentium reached the highest 
density, mucus thickness remained as low as day 4 post infection, followed by 
substantial goblet cell depletion with a reduction of the total amount of mucin inside 
the goblet cells. In addition, at this time point, the organized adherent inner mucus 
layer present in uninfected mice was not found in the infected mice. From day 14 
post infection, when the bacterial density reduced to day 19 which is when there was 
the clearance of infection, there was a continuous increase in the number of goblet 
cells, and the mucus layer reached the greatest thickness, which was even more than 
non-infected animals. At day 14 the mucin engorgement decreased to its lower level, 
which could be based on the release of mucins into the mucus layer. Figure 3 
summarizes the changes during the time course of infection. 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Schematics of changes in goblet cells during C. rodentium infection in 
WT mice. The total amount of mucin inside the goblet cells shown in different 
shades of gray to indicate the intensity of stored mucins. Black is used for the highest 
amount of mucin inside the goblet cells. The thickness of the mucus layer is shown as 
a gray surface for the organized adherent inner mucus layer, and curled lines indicate 
an unorganized layer.    
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To examine the effect of the cytokine environment on the changes of mucins and 
mucus layer, we compared differences in mucin synthesis and the mucus layer 
thickness between wild-type (WT) and interferon deficient mice (IFN-γ-/-), since 
previous data demonstrated the importance of the Th1 response, especially the IFN-γ 
cytokine in protection against C. rodentium infection [176,190]. The outcome 
showed that at the time point of infection with the highest bacterial load, IFN-γ-/- 
mice had a thicker mucus layer, more engorgement of mucins and less goblet cell 
depletion compared to the WT mice (paper IV).  
We then examined the effect of cytokines involved in the Th1/Th2 response, 
individually or as a combination with and without C. rodentium/ETEC infection, on 
our recently developed in vitro mucosal surfaces. Selections of cytokines were based 
on the differences in their expression level in WT versus IFN-γ-/- mice at day 10 post 
infection, and/or the gene upregulation during the clearance phase, when the mucus 
layer is enhanced (Table1). 
 
In vivo infection IFN-γ TNF-α IL-12 IL-6 IL-4 IL-13 
mRNA level  10 d p.i in IFN-γ-/- 
and WT mice  ↓ - ↓ ↑ ↑ ↑ 
mRNA level of WT mice during 
clearance (day 14 and19 post 
infection) 
↑ ↑ ↑ ↑ ↑ ↓ 
 
Table 1. Changes in the mRNA level of cytokines involved in Th1/Th2 response during C. 
rodentium infection.   
 
 A summary of the outcome of the study is shown in Table 2. In the absence of 
infection, treatment with the Th1 cytokines (IFN-γ, TNF-α) and their combination 
reduced the number of goblet cells and the morphology score of the membranes, 
which is an indicator of mucin engorgement in the surface goblet cells. In contrast, 
IL-4 and IL-13, which are cytokines involved in the Th2 response, increased the 
number of goblet cells and enhanced the bulkiness of the surface goblet cells. 
Infection with C. rodentium seemed to reverse the effect of cytokine treatments on 
the in vitro mucosal surfaces, making them more similar to untreated membranes. 
Infection with ETEC had the same nullifying effect as C. rodentium on the 
membranes treated with IFN-γ and TNF-α, although, they did not reverse the 
morphological enhancement caused by IL-4 and IL-13. Infection with these 
pathogens had no effect on the membranes treated with the combination of IFN-γ and 
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TNF-α with and without the addition of IL-4. In general, these results indicated 
changes in the goblet cells, mucin and mucus layer during infection is dependent on 
the combined impact of the pathogen and cytokines. Therefore, these parameters 
should be considered in parallel during the studies on the interaction between mucin 
and pathogens.  
 
In vitro: Non-
infected IFN-γ TNF-α 
IFN-γ 
+  
TNF-α 
IFN-γ + 
TNF-α + 
IL-4 
IL-12 IL-6 IL-4 IL-13 
Effects on 
Morphology of  in 
vitro mucosal 
surface 
↓*** ↓*** ↓*** ↓*** ↑ x ↑* ↑ 
Effects on goblet 
cell density of  in 
vitro mucosal 
surface 
↓ ↓** ↓*** ↓*** ↑ ↑** ↑* No 
         
In vitro:  
C. rodentium 
infection 
IFN-γ TNF-α 
IFN-γ 
+  
TNF-α 
IFN-γ + 
TNF-α + 
IL-4 
IL-12 IL-6 IL-4 IL-13 
Effects on 
Morphology 
compared to the 
non-treated of  in 
vitro mucosal 
surface 
No No ↓*** ↓*** No No No No 
Effects on 
Morphology 
compared to the  
same treatment in 
the non-infected  
in vitro mucosal 
surface 
No No No No ↓*** No ↓* ↓* 
Effects on goblet 
cell density 
compared to the 
non-treated  in 
vitro mucosal 
surface 
No No ↓** ↓* No No No No 
Effects on goblet 
cell density 
compared to the 
same treatment in 
the non-infected 
in vitro mucosal 
surface 
No No ↓*** ↓*** No No No No 
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In vitro: ETEC 
infection IFN-γ TNF-α 
IFN-γ 
+  
TNF-α 
IFN-γ + 
TNF-α + 
IL-4 
IL-12 IL-6 IL-4 IL-13 
Effects on 
Morphology 
compared to the 
non-treated of  in 
vitro mucosal 
surface 
No No ↓*** ↓*** No No No No 
Effects on 
Morphology 
compared to the 
same treatment in 
the non-infected  
in vitro mucosal 
surface 
No ↑*** No No No ↓* No No 
Effects on goblet 
cell density 
compared to the 
non-treated  in 
vitro mucosal 
surface 
No No ↓*** ↓*** No No No No 
Effects on goblet 
cell density 
compared to the 
same treatment in 
the non-infected 
in vitro mucosal 
surface 
No No ↓*** ↓** No No No No 
         
Table 2. Summary of changes in morphology and goblet cell density of in vitro mucosal 
surfaces treated with Th1/Th2 cytokines, with and without C. rodentium/ETEC infection. 
Statistics: One-way ANOVA, Bonferroni post hoc’s, *˂0.05, **˂0.001, ***˂0.0001. (n=4-12) 
The epithelial response to ion transport secretory stimulators 
(Paper II, III) 
The presumption of the epithelial tissue as an electrical circuit, is the basis for the 
commonly used Ussing chamber method for measurement of the electrical 
parameters of epithelial layers. In this method, the membrane current (Im) and 
transepithelial potential (PD) is used to measure the active transport of ions across 
the epithelium, epithelial resistance (Rp) to monitor tissue integrity [191-193], and 
membrane capacitance (Cp) to study exocytosis of mucins of single cells and 
cultured epithelial monolayers [194-196]. In our project, we used the measurement of 
the electrical parameters as a baseline to compare the ability of different 
gastrointestinal cell lines in the production of integrated in vitro epithelial surfaces. A 
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low resistance and a fluctuating PD were related to the inability of the cell lines to 
produce an adherent monolayer with tight junctions. This was in line with the results 
of PAS/Alcian blue staining of the membranes that showed unorganized layers of 
cells. Among the tested cell lines, T84, Caco2, LS513, HT29 MTX-P8 and HT29 
MTX-E12 intestinal cells produced a layer with a high resistance (over 100 Ω*cm2), 
while MKN7 was the only gastric cell line that provided a resistance (paper II). We 
also measured the Rp and PD of the mice colonic epithelial layer during C. 
rodentium infection, to compare the electrophysiological changes of this layer during 
different phases of infection. The outcome showed a substantial reduction of Rp and 
PD during the most severe colitis at day 10 and 14 post infection, although the 
magnitude of these parameters correlated weakly with the colitis score. Since we 
detected the low level of Rp and PD in the in vitro surfaces is associated with the 
lack of membrane integrity, we can speculate that the decrease of these electrical 
parameters in the infected mice is related to the increase of paracellular permeability. 
This is also in line with previous studies that demonstrated an increase in paracellular 
permeability in C. rodentium infected mice [197].  
 
 
 
 
 
 
 
 
 
 
Figure 4. The response to forskolin and charbachol is altered during infection in 
distal colon explants studied in Ussing chambers. Changes in Im (A and C) and Rp 
(B and D) in response to forskolin (A-B) and charbachol (C-D) in distal colonic 
tissue during C. rodentium infection of WT and IFN-γ-/- mice. Statistics: ANOVA 
bonferroni’s post hoc test, *p<0.05, **p<0.001 and ***p<0.0001vs day 0 of the WT 
mice, # p<0.05 and ## p<0.001 vs day 0 of IFN-γ-/- mice. (n=8-17) 
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We also measured the electrical parameters of the in vitro mucosal surfaces to study 
the ability of different cell lines in response to the secretagogues such as carbachol 
(CCh) and forskolin, which are involved in activation of the ion secretion pathway. 
The existing data on CCh demonstrated its effect on induction of the mucus secretion 
in the small and large intestine [198,199]. In vitro experiments demonstrated that 
stimulation with CCh is mediated via the Ca2+ pathway of ion secretion, and only 
induced secretory responses in LS513 cells, which is a goblet cell-like cell line, and 
had no effect on enterocyte-like cell line Caco-2 (paper III). We also detected mucus 
release from the other goblet cell-like cell lines (HT29 MTX-P8 and HT29 MTX-
E12) into the mucus layer, in response to addition of CCh to the basolateral side of 
the membranes. This effect was detected by an increase in the epithelial capacitance, 
and PAS/Alcian blue staining of the membranes (paper II). In addition, both goblet 
cell-like and enterocyte-like cell lines demonstrated changes in Im and Rp, which 
reflected ion channel activity in the epithelium, in response to stimulation with 
forskolin, which mediates the cAMP pathway of ion secretion. The ability of in vitro 
mucosal surfaces in responding to these stimulators is important for the infection 
studies, as evidence showed that during infection and inflammation, enteric 
pathogens induced mucus and fluid secretion, which coincides with ion secretion. 
The ion secretion may contribute to mucus hydration and clearance of pathogens, 
although the molecular mechanism of the process and the relative importance of 
chloride and bicarbonate secreted by these ion channels, in this pathway is not fully 
understood. However, recent experiments with mice ileum showed the importance of 
bicarbonate for the formation of a normal mucus layer, as it could expand the stored 
Muc2 mucin at secretion [29]. 
In our in vivo studies, there was a gradual decrease in the Rp of the colonic explant of  
C. rodentium infected WT mice in response to both forskolin and CCh from day 0 to 
day 14 post infection which was restored to the pre-infection level after clearance 
(day 19 post infection). However, only CCh could change the Im and forskolin had 
no effect (paper III). In contrast, the Im of IFN-γ-/- mice had a noticeable increase in 
response to forskolin stimulation at day 10 post infection (Figure 4A). Stimulation 
with either CCh or foskolin, however, had no effect on changes in Im and Rp of the 
non-infected WT and IFN-γ-/- (Figure 4A-D). This could indicate higher activity of 
ion channels in IFN-γ-/- mice during infection, which coincides with the increase of 
mucus thickness in these mice at the same time point.  
In summary, these results demonstrate that the electrochemical parameters and the 
ion transport of the epithelial layer changes during infection, and this variation also 
extended to the changes in response to different stimuli. Interestingly, the increase of 
mucus thickness in both WT and IFN-γ-/- mice coincide with the altered ion channel 
activities.  
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Mucin production rate and turnover in the gastrointestinal 
infection (Paper I and IV) 
Penetration of pathogens into the protective mucus barrier could result in 
modification of the structure and synthesis of mucins that are the main component of 
the mucus layer. The changes in mucin synthesis and secretion could be regulated by 
pathogens and/or components of the immune response [45]. However, there is a gap 
of knowledge about the effect of different pathogens and cytokines on mucin 
synthesis during infection. In this work, using labeling of the O-linked mucin type 
glycans, we investigated the effect of gastrointestinal pathogens as well as cytokines 
involved in the response to these pathogens, on the biosynthesis of mucins. The 
method is applicable both in vitro and in vivo and is based on incorporation of the 
GalNAc analogue GalNAz into the mucins during biosynthesis. The visualization 
occurs using click-it chemistry that attaches a fluorescent alkyne to the incorporated 
GalNAz [200,201]. Previous results from the murine distal colon reported a duration 
of 6 to 8 h from incorporation of GalNAz to release of the labeled mucin to the 
lumen [202]. Therefore, we performed a 12 h study to obtain the basal production 
rate and turnover of mucin in both murine stomach and the intestinal in vitro mucosal 
surfaces. The metabolic incorporation of GalNAz into the newly synthesized 
glycoproteins was detected from the first hour after injection/addition both in vivo 
and in vitro. The newly synthesized mucins were localized at the supra nuclear part 
of the surface epithelial cells/goblet cells after 1 h of GalNAz incorporation. During 
the second and third hours, the mucins moved through the cells toward the cell 
surface. Five hours after injection, a slight difference was detected between the two 
systems. In the surface cells of the murine stomach, some newly synthesized mucins 
were detected on the cell surface, whereas some remained inside the cell, while, in 
the in vitro mucosal surfaces, some of the goblet cells have released their GalNAz 
labeled mucin into the mucus layer. The traces of the newly synthesized mucins in 
the murine gastric mucus layer were detected after 6 h of injection, although in both 
systems, the mucins could still be detected inside the majority of the cells. During the 
time points of 6 to 11 h post addition of GalNAz into the in vitro model, the 
proportion of cells having released their newly synthesized mucins into the mucus 
layer increased with time, and after 12 h most of the goblet cells had released their 
GalNAz labeled mucins to the lumen. The same trend was detected in the murine 
stomach, although even after 12 h some of the surface epithelial cells still had not 
released their newly synthesized mucins. Based on these results, we chose the major 
transitional stages of the mucin turnover: the transfer to the cytoplasm, the start point 
of the release of the mucin to the mucus layer, and the time point that most of the 
cells have released their newly synthesized mucins into the mucus layer, to study the 
effect of different cytokines and pathogenic infection on mucin turnover. Therefore, 
the time points for in vitro study were slightly different from the in vivo experiments.  
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 In vitro: Non-infected IFN-γ TNF-α IL-12 IL-6 IL-4 IL-13 
Effects on turnover of  in vitro 
mucosal surface ↓ ↓ ↓ ↑ ↑ ↑ 
       
In vitro: C. rodentium 
infection IFN-γ TNF-α IL-12 IL-6 IL-4 IL-13 
Effects on turnover compared 
to the non-treated in vitro 
mucosal surface 
↑ ↓ ↑ ↑ ↑ ↑ 
Effects on turnover compared 
to same treatment in  the non-
infected  in vitro mucosal 
surface 
↑ ↓ ↑ ↑ ↑ ↑ 
       
In vitro: ETEC infection IFN-γ TNF-α IL-12 IL-6 IL-4 IL-13 
Effects on turnover compared 
to the non-treated in vitro 
mucosal surface 
↑ ↑ ↑ ↑ ↑ ↑ 
Effects on turnover compared  
to the same treatment in  the 
non-infected  in vitro mucosal 
surface 
↑ ↑ ↑ ↑ ↑ ↑ 
       
Table 3. Mucin turnover in intestinal in vitro mucosal surfaces treated with Th1/Th2 
cytokines with and without C. rodentium/ETEC infection.  
 
The outcome of the pulse study in the antrum of the H. pylori infected mice 
demonstrated a reduction in rate and turnover of mucin compared to the non-infected 
mice (paper I). The effect was more prominent in the early colonization than in 
chronic infection. The results also showed a slower production rate and transfer of 
the GalNAz labeled mucin in the corpus compared to the antrum of non-infected 
mice, and this difference was more pronounced during infection (paper I). No 
difference was detected in the rate and turnover of mucin synthesis in the corpus of 
non-infected mice and mice with early colonization (paper I). In contrast to the 
inhibitory effect of H. pylori in vivo, infection of the intestinal in vitro mucosal 
surfaces with either C. rodentium or ETEC increased the rate and turnover of the 
newly synthesized mucin, and ETEC had a more accelerating effect (paper IV). The 
changes in mucin rate and turnover were also detectable in the cells treated with 
different cytokines involved in the Th1/Th2 response (Table 1 and paper IV). In the 
absence of infection, the Th1 cytokines (IFN-γ, TNF-α and IL-12) reduced the 
incorporation of GalNAz and turnover of the newly synthesized mucins, whereas 
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Th2 cytokines (IL-4, IL-13 and IL-6) had a stimulatory effect (Table 3 and paper IV). 
In summary, these results indicated that the turnover of mucin is tissue specific, and 
the cytokine environment as well as pathogens have an important role in the 
regulation of mucin synthesis and turnover. Indeed, infection of the intestinal in vitro 
mucosal surface with C. rodentium and ETEC demonstrated that bacterial infection 
might overcome the effect of cytokines on goblet cells.   
 
Nazanin Navabi 
33 
DISCUSSION 
In vitro mucosal surfaces – a model for infection studies 
In the present thesis, the aim was to study the effect of bacterial infection on the 
mucus layer and mucins as the main component of the defensive barrier of the 
gastrointestinal tract. First, we developed a method of cell culture to produce an in 
vivo like in vitro mucosal surfaces from intestinal cell lines and used it in parallel to 
the in vivo infection studies in mice. A suitable in vitro model is required as most of 
the enteric pathogens, including the ones that are the main focus of this thesis, are 
host specific. Therefore, the studies on animal models are not optimal for 
understanding the interaction between host and pathogens during colonization and 
infection. In addition, the standard methods of cell culture that are used in many 
studies cannot produce a polarized epithelial layer, which is an important factor in 
bacterial adhesion and invasion as well as producing a host immune response to the 
invading pathogens [203,204]. Furthermore, the common cell lines used for the in 
vitro infection studies have a highly variable expression of mucins and have very low 
production of gel forming-mucins [186]. Our semi-wet interface culture with 
mechanical and chemical stimulation produced an adherent polarized epithelial layer, 
with functional tight junction and relatively thick mucus layer from HT29 MTX (-P8 
and -E12) intestinal cell lines. The results of immunohistochemical studies indicated 
that HT29 MTX (-P8 and -E12) among the tested cell lines, had the greatest 
resemblance to the human colon mucin profile. In addition, infection of the in vitro 
mucosal surfaces with different pathogens, especially Citrobacter jejuni, located the 
majority of bacteria in the mucus layer in close contact to MUC2. The binding is 
important in preventing the invasion of the epithelial surface by pathogens and was 
also detected during Citrobacter jejuni infection in chicken and human [45,205]. 
Furthermore, since massive discharge of mucins from mucin producing cells in 
response to microbial products or components of immune response is an important 
aspect in infection studies [49-58], the ability of the in vitro model in releasing 
mucins in response to  stimuli such as CCh [46], increases the similarity of  this in 
vitro model to the in vivo environment. In summary, the methods developed herein, 
create in vitro mucosal surfaces suitable for host-pathogen interaction studies at the 
mucosal surface.  
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Effect of infection and cytokine environment on mucins and 
mucus layer  
In the studies for this thesis, we investigated the distinct aspects of the mucus layer 
and mucins, to gain a better understanding of the effect of infection and the cytokine 
environment on mucin production and synthesis. Our main focus was the C. 
rodentium infection as a model for A/E pathogens. We investigated the effect of 
infection on changes in the number of goblet cells, the amount of stored mucin inside 
the goblet cells, thickness of the adherent mucus layer, mRNA level of different 
mucins, the electrophysiological properties of the colonic epithelia, and gene 
expression of cytokines involved in the Th1/Th2 response during the time course of 
infection. The difference between our work and other studies in this field is that 
usually in the infection experiments, the focus is only on one aspect of mucin 
synthesis. Most of the results are based on the mRNA level which is the basal level 
of mucin synthesis [50,76,78,79,132,133]. However, the mature mucin which is 
released from the cell into the cell surface or mucus layer is subjected to a great deal 
of post-translational modification, especially glycosylation, which plays an important 
role in type, rate and turnover of mucin production [15]. In our studies neither the 
enhanced mucus thickness found during clearance in the WT mice, nor the increased 
mucus thickness observed in the IFN-γ-/- mice during infection could be explained by 
changes in mucin mRNA level. Therefore, it is important to combine mRNA 
measurement with studies on other aspects of the mucin glycoprotein life cycle.   
The results from infection of the WT mice with C. rodentium showed mucus 
transcription and secretion are dynamically altered, and clearance of the infection 
coincides with the reformation of the organized inner mucus layer and the increase of 
mucus thickness. This increase in mucus layer suggested the involvement of mucins 
in removing the pathogens, which is in line with previous work that described the 
role of mucus in the removal of nematode infections [206,207]. In addition, during 
clearance of C. rodentium we detected an increase in ion channel activity compared 
to the highpoint of infection, when mucus thickness was decreased. The change in 
ionic composition was also detected in our mRNA and proteomics experiments. 
These results are further supported by the outcome of the study on the IFN-γ-/- mice 
that showed during the highpoint of infection, that these mice had a thicker mucus 
layer which again coincided with more activation of ion channels. As ion channels 
and their secreted Ca2+ ions and bicarbonate are suggested to be important to the 
packing and release of mucins [24-27], we speculate that the change in ion channel 
activity during clearance is to facilitate mucin release.  
Furthermore, as discussed extensively in the Introduction, current knowledge 
indicates the effect of cytokines on goblet cell differentiation and the production rate 
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of mucins [50,56,68,74,75,77,78,80]. Therefore, we analyzed the mRNA of different 
cytokines involved in Th1/Th2 response in IFN-γ-/- and WT mice and detected a 
tendency toward the Th2 response in the absence of IFN-γ. The Th2 cytokine profile 
of the IFN-γ-/- mice coincided with the thicker mucus layer in these mice compared to 
C. rodentium infected WT mice. The change of cytokine environment toward a Th2 
response is also detected in the mRNA analysis of cytokines in WT mice during the 
clearance of C. rodentium infection, when the mucus layer thickness is increased. In 
addition, the outcome of the treatment of in vitro mucosal surfaces with IL-4 and IL-
13, that are cytokines involved in Th2 response, demonstrated an increase in the 
engorgement of the surface goblet cells and mucin synthesis, whereas Th1 cytokines 
had an inhibitory effect. The increase of Muc2 and Muc3 mRNA level and goblet 
cell hyperplasia in response to Th2 cytokines has been shown in the murine intestinal 
parasitic infections [78,79]. However, in the parasitic infection, the IL-13 cytokine 
was involved in induction of the mucin synthesis [78,79], while our experiments both 
in vivo and in vitro demonstrated a prominent effect of IL-4 in stimulation of mucin 
synthesis and turnover. 
Changes in mucin rate and turnover in response to cytokine 
environment and infection  
Changes in mucin synthesis and turnover in response to stimulators have been 
described in previous studies. The methods used are mainly based on PAS/alcian 
blue staining, immunohistochemical staining, measurement of the electrical 
parameters of the epithelial surface, and in some studies, radioactive labelling to 
quantify the freshly produced and secreted mucins [68,208-210]. In the present work, 
in addition to the common methods, we used a non-radioactive metabolic 
incorporation of acetylated GalNAz to the newly synthesized mucin. This method 
enabled us to follow the movement of the GalNAz labeled mucin from the time of 
translocation to the supra nuclear area of the cells and their release into the mucus 
layer, both in vivo and in vitro. The results from the stomach of non-infected mice 
and the intestinal in vitro model, along with the previous results from the murine 
distal colon [202] indicated that mucin synthesis and turnover is tissue and cell 
specific, and the renewal of mucin is faster in the intestine compared to the stomach. 
Furthermore, the results from the treatment of the in vitro mucosal surfaces with 
different cytokines indicated a reduction in rate and turnover of mucin in response to 
cytokines involved in Th1 response, whereas Th2 response cytokines increased the 
mucin synthesis and turnover. This was in line with a previously published 
experiment using an allergic model, where Th2 cells were intravenously transferred 
into mice, resulting in high levels of IL-4 and increased levels of Alcian blue/PAS 
stained mucins in the tissue [211]. Conversely, transfer of twice the number of Th1 
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along with Th2 cells (2:1), considerably decreased the amount of Alcian blue/PAS 
stained mucins [212]. However, our results from the infection of these treated cells 
with C. rodentium/ETEC demonstrated that bacterial invasion can overcome the 
effect of Th1 cytokines and induce the mucin synthesis and turnover in the cells 
treated with these cytokines, and accelerate the stimulation of cells treated with Th2 
cytokines. Even non-treated cells showed an increase in rate and turnover of mucins 
in response to infection with C. rodentium/ETEC. In contrast, infection with H. 
pylori in mice reduced the rate of mucin synthesis and turnover mainly in the antrum.   
In general, when comparing the results of infection studies with H. pylori, C. 
rodentium and ETEC presented in this thesis, it is important to consider the 
differences between in vitro and in vivo environment, bacterial density and duration 
of infection. As shown previously, during in vivo infections, in addition to the effect 
of microbial products and individual cytokines used in our in vitro study, a range of 
environmental stimuli can alter the rate of mucin release, including cholinergic 
stimuli, lipopolysaccharide, bile salts, nucleotides, nitric oxide, vasoactive intestinal 
peptides and neutrophil elastase [50,51,54-56,213,214]. In addition, effect of duration 
of infection on changes of mucins is detected during in vitro studies. For example, 
short time incubation of a human gastric mucosa biopsy segment with 
lipopolysaccharide from H. pylori resulted in rapid mucin discharged, whereas 
prolonged incubation led to a concentration-dependent decrease in mucin synthesis 
and secretion [215]. Similar results were observed during in vitro infection of the 
intestinal goblet cells by viable H. pylori [215].     
Changes of mucin and mucus layer, during infection in gastric 
mucosa 
We have also studied the effect of H. pylori infection on the murine gastric mucosa, 
which demonstrated a decrease in Muc1 during early colonization and chronic 
infection. The Muc5ac levels also suggested a decrease, albeit it was not statistically 
significant. However, due to the lack of a proper preservation method and probable 
differences in the properties of the inner adherent layer between stomach and colon 
[6,216], we did not succeed in preserving the mucus layer in the stomach. It has been 
shown that preserving colon along with luminal material helps in keeping the mucus 
layer intact [217]. Nevertheless, despite our effort to preserve the whole stomach 
with the luminal material, most of the inner mucus layer was lost, and the remains 
were only detectable as patches on the epithelial surface. In addition, culture of 
gastric cells with the different methods did not improve the morphology of cells as 
detected in intestinal cell lines. Only MKN7 cells could produce an adherent 
polarized layer, but lacked the adherent mucus layer. In summary, these 
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methodological problems are obstacles in the studies of the gastric mucus layer and 
mucins during infection. To improve the understanding of the interaction between 
gastric pathogens and mucosal surfaces, there is a need to improve the existing 
methods or providing new methods compatible to the gastric mucosal surface. 
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CONCLUSIONS 
The main focus of this thesis was to investigate the changes in mucins and the mucus 
layer in the gastrointestinal tract during infection with the gastrointestinal pathogens 
C. rodentium (a mouse model for intestinal A/E pathogens), ETEC and H. pylori. To 
be able to compare the results from murine studies to the effect of infection in 
humans, we needed an in vitro mucosal surface to have the most resemblance to the 
in vivo environment.  Therefore, we developed a method of culture to create in vitro 
model suitable for studies of host-pathogen interactions at the mucosal surface. Our 
main findings were: 
 The semi-wet interface culture in combination with mechanical 
stimulation and DAPT treatment caused HT29 MTX-P8, HT29 
MTX-E12, LS513 and to some extent, Caco-2 and T84 intestinal 
cells to polarize, form functional tight junctions and produce an 
adherent mucus layer. 
 
 H. pylori colonization in the mucus niche of the murine stomach in 
vivo leads to decreased mucin production and secretion rate and 
decreased levels of Muc1 in the mucosa.  
 
 During self-limiting infection of C. rodentium in WT mice, mucus 
transcription and secretion are dynamically altered in response to 
the infection and the clearance of the infection coincides with the 
reformation of the organized inner mucus layer and an increased 
mucus thickness. 
 
 The increase in mucus thickness during C. rodentium clearance 
coincided with altered ion channel activities.  
 
 Changes in the cytokine environment in vivo has a huge effect on 
mucus thickness, as infection of IFN-γ-/- mice with C. rodentium 
resulted in a vastly enhanced mucus thickness compared to the 
WT animals. 
 
 Both the cytokine profile and the pathogen species affect the 
production rate and turnover of mucins, and the presence of the 
Th2 cytokines accelerated the process of mucin synthesis.  
 
 39 
ADDITIONAL BIBLOGRAPHY 
 
Skoog EC, Sjoling A, Navabi N, Holgersson J, Lundin SB, et al. (2012) 
Human gastric mucins differently regulate Helicobacter pylori 
proliferation, gene expression and interactions with host cells. PLoS One 
7: e36378. 
 
Mucus and mucins during gastrointestinal infections 
40 
ACKNOWLEDGEMENT 
This thesis is a result of a quest for knowledge that started from the first day of the 
school, and I would like to thank each and every person who guided, encouraged or 
inspired me during these years. My special gratitude is to: 
My main supervisor Sara Linden, I admire your knowledge, enthusiasm and I am 
grateful that you believed in me. Thank you for your never ending support. You 
taught me to think and work independently, encouraged my ideas and motivated me.   
My co-supervisors Gunnar and Henrik, thank you for your help and support.  
All the past and present members of the MIC team for contributing to such a nice 
working environment.  
Emma, for being a wonderful friend and colleague, and a great company during our 
scientific trips. For all the guidance and help with the PhD rules during these years. I 
wish you a lot of success in the rest of your career.  
Harvey, you are always ready to share your knowledge and I learned a lot from you. 
I am especially grateful that you take the time to read through this thesis.  
Pushpa, for your helps and support during these years, and for being a great friend.  
Debashish, for all the talks during these years, you are always ready to help 
everyone.  
Macarena, Medea and Jonas, for your friendship and kindness. Elsa, Arpan, 
Omid and Anna. 
A special thanks to Åsa Sjöling, you were always ready to teach me and answer my 
questions. I had your support from the day I started my Master thesis and could 
always count on your help.  
Sukanya and Malin Johansson, for your contributions to the work and your advice 
on the methods. 
All members of the mucin biology, Susann and Niclas’s group you have all provided 
a great and friendly atmosphere and it has been a pleasure working with all of you. I 
would like to especially thank Jenny, for always being ready to answer my questions 
about the Ussing method, and Karin for all your helps. Sara Flowers, I am so 
grateful for your moral supports and kindness, especially during these last months.  
 41 
The people in the department of microbiology and immunology for letting me use 
the equipment and all their helps. Specially:  
Ali Harandi, my Master thesis supervisor, for introducing me to the research world 
and for his endless support. Also to the members of the group, Josefine, Madelene 
and Karolina, you are the best friends and co-workers. I learned a lot of methods and 
lab routines from you.  
Linda Löfbom, for being a great friend, I could always count on your help and 
support. Thank you. 
Margareta and Anneli, you were always ready to answer my questions and guided 
me a lot during the H. pylori  infection.  
Julia and Maria from the center for cellular imaging for the instructions during 
work with confocal microscope. 
I would also like to thank the Tony Hollingsworth and all the members of his group 
specially Tom, Paul and Jim for scientific discussions, your collaboration and your 
hospitality during the time I spent in your lab.  
The organizers of Forum GIMIICum, you managed to broader my vision with your 
wonderful courses. Also to members of the Forum for the grate scientific discussions, 
and the fun times we had during our gatherings.  
My mom and dad for teaching me to work hard and be independent, and my sister 
for the constant encouragements.  
A special thank to my son Sohrab, for your patience during these years. It was not 
easy to have a mom who was always busy studying, but you understood and gave me 
strength.  
A huge thank to my wonderful husband. Mansur without you and your support I 
could never finish this thesis. You were always there, listening  to me, supporting 
me, and encouraging me. Thank you for your patience, especially during these last 
months.  
 
Mucus and mucins during gastrointestinal infections 
42 
REFERENCES 
 
1. Naja F, Kreiger N, Sullivan T (2007) Helicobacter pylori infection in 
Ontario: prevalence and risk factors. Can J Gastroenterol 21: 501-
506. 
2. Barker N, van de Wetering M, Clevers H (2008) The intestinal stem cell. 
Genes Dev 22: 1856-1864. 
3. Atuma C, Strugala V, Allen A, Holm L (2001) The adherent 
gastrointestinal mucus gel layer: thickness and physical state in vivo. 
Am J Physiol Gastrointest Liver Physiol 280: G922-929. 
4. Patsos G, Corfield A (2009) Management of the human mucosal defensive 
barrier: evidence for glycan legislation. Biol Chem 390: 581-590. 
5. Hansson GC (2012) Role of mucus layers in gut infection and 
inflammation. Curr Opin Microbiol 15: 57-62. 
6. Ermund A, Schutte A, Johansson ME, Gustafsson JK, Hansson GC (2013) 
Studies of mucus in mouse stomach, small intestine, and colon. I. 
Gastrointestinal mucus layers have different properties depending on 
location as well as over the Peyer's patches. Am J Physiol 
Gastrointest Liver Physiol 305: G341-347. 
7. Schade C, Flemstrom G, Holm L (1994) Hydrogen ion concentration in the 
mucus layer on top of acid-stimulated and -inhibited rat gastric 
mucosa. Gastroenterology 107: 180-188. 
8. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA (2008) 
Mucins in the mucosal barrier to infection. Mucosal Immunol 1: 183-
197. 
9. Loomes KM, Senior HE, West PM, Roberton AM (1999) Functional 
protective role for mucin glycosylated repetitive domains. Eur J 
Biochem 266: 105-111. 
10. Johansson ME, Sjovall H, Hansson GC (2013) The gastrointestinal 
mucus system in health and disease. Nat Rev Gastroenterol Hepatol 
10: 352-361. 
11. Lamont JT (1992) Mucus: the front line of intestinal mucosal defense. 
Ann N Y Acad Sci 664: 190-201. 
12. Linden SK (2004) Helicobacter pylori binding to gastric mucins and host 
glycosylation changes after inoculation. Thesis Title. 
13. McCool DJ, Okada Y, Forstner JF, Forstner GG (1999) Roles of 
calreticulin and calnexin during mucin synthesis in LS180 and 
HT29/A1 human colonic adenocarcinoma cells. Biochem J 341 ( Pt 
3): 593-600. 
14. Ho JJ, Jaituni RS, Crawley SC, Yang SC, Gum JR, et al. (2003) N-
glycosylation is required for the surface localization of MUC17 
mucin. Int J Oncol 23: 585-592. 
 43 
15. Strous GJ, Dekker J (1992) Mucin-type glycoproteins. Crit Rev Biochem 
Mol Biol 27: 57-92. 
16. Pigny P, Guyonnet-Duperat V, Hill AS, Pratt WS, Galiegue-Zouitina S, 
et al. (1996) Human mucin genes assigned to 11p15.5: identification 
and organization of a cluster of genes. Genomics 38: 340-352. 
17. Gum JR, Jr., Hicks JW, Toribara NW, Siddiki B, Kim YS (1994) 
Molecular cloning of human intestinal mucin (MUC2) cDNA. 
Identification of the amino terminus and overall sequence similarity 
to prepro-von Willebrand factor. J Biol Chem 269: 2440-2446. 
18. Asker N, Baeckstrom D, Axelsson MA, Carlstedt I, Hansson GC (1995) 
The human MUC2 mucin apoprotein appears to dimerize before O-
glycosylation and shares epitopes with the 'insoluble' mucin of rat 
small intestine. Biochem J 308 ( Pt 3): 873-880. 
19. Asker N, Axelsson MA, Olofsson SO, Hansson GC (1998) Dimerization 
of the human MUC2 mucin in the endoplasmic reticulum is followed 
by a N-glycosylation-dependent transfer of the mono- and dimers to 
the Golgi apparatus. J Biol Chem 273: 18857-18863. 
20. Sheehan JK, Kirkham S, Howard M, Woodman P, Kutay S, et al. (2004) 
Identification of molecular intermediates in the assembly pathway of 
the MUC5AC mucin. J Biol Chem 279: 15698-15705. 
21. Thornton DJ, Davies JR, Kraayenbrink M, Richardson PS, Sheehan JK, 
et al. (1990) Mucus glycoproteins from 'normal' human 
tracheobronchial secretion. Biochem J 265: 179-186. 
22. Perez-Vilar J, Hill RL (1999) The structure and assembly of secreted 
mucins. J Biol Chem 274: 31751-31754. 
23. Hasnain SZ, Gallagher AL, Grencis RK, Thornton DJ (2013) A new role 
for mucins in immunity: insights from gastrointestinal nematode 
infection. Int J Biochem Cell Biol 45: 364-374. 
24. Verdugo P, Aitken M, Langley L, Villalon MJ (1987) Molecular 
mechanism of product storage and release in mucin secretion. II. The 
role of extracellular Ca++. Biorheology 24: 625-633. 
25. Verdugo P, Deyrup-Olsen I, Aitken M, Villalon M, Johnson D (1987) 
Molecular mechanism of mucin secretion: I. The role of intragranular 
charge shielding. J Dent Res 66: 506-508. 
26. Ambort D, Johansson ME, Gustafsson JK, Nilsson HE, Ermund A, et al. 
(2012) Calcium and pH-dependent packing and release of the gel-
forming MUC2 mucin. Proc Natl Acad Sci U S A 109: 5645-5650. 
27. Ambort D, Johansson ME, Gustafsson JK, Ermund A, Hansson GC 
(2012) Perspectives on mucus properties and formation--lessons from 
the biochemical world. Cold Spring Harb Perspect Med 2. 
28. Quinton PM (2008) Cystic fibrosis: impaired bicarbonate secretion and 
mucoviscidosis. Lancet 372: 415-417. 
29. Gustafsson JK, Ermund A, Ambort D, Johansson ME, Nilsson HE, et al. 
(2012) Bicarbonate and functional CFTR channel are required for 
Mucus and mucins during gastrointestinal infections 
44 
proper mucin secretion and link cystic fibrosis with its mucus 
phenotype. J Exp Med 209: 1263-1272. 
30. Vidyasagar S, Rajendran VM, Binder HJ (2004) Three distinct 
mechanisms of HCO3- secretion in rat distal colon. Am J Physiol 
Cell Physiol 287: C612-621. 
31. Loo DD, Kaunitz JD (1989) Ca2+ and cAMP activate K+ channels in the 
basolateral membrane of crypt cells isolated from rabbit distal colon. 
J Membr Biol 110: 19-28. 
32. Dagher PC, Rho JI, Charney AN (1993) Mechanism of bicarbonate 
secretion in rat (Rattus rattus) colon. Comp Biochem Physiol Comp 
Physiol 105: 43-48. 
33. Bachmann O, Reichelt D, Tuo B, Manns MP, Seidler U (2006) Carbachol 
increases Na+-HCO3- cotransport activity in murine colonic crypts 
in a M3-, Ca2+/calmodulin-, and PKC-dependent manner. Am J 
Physiol Gastrointest Liver Physiol 291: G650-657. 
34. Hirota CL, McKay DM (2006) Cholinergic regulation of epithelial ion 
transport in the mammalian intestine. Br J Pharmacol 149: 463-479. 
35. Yu K, Lujan R, Marmorstein A, Gabriel S, Hartzell HC (2010) 
Bestrophin-2 mediates bicarbonate transport by goblet cells in mouse 
colon. J Clin Invest 120: 1722-1735. 
36. Linden SK, Florin TH, McGuckin MA (2008) Mucin dynamics in 
intestinal bacterial infection. PLoS One 3: e3952. 
37. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA (2003) Cell 
signaling through membrane mucins. Bioessays 25: 66-71. 
38. Bork P, Patthy L (1995) The SEA module: a new extracellular domain 
associated with O-glycosylation. Protein Sci 4: 1421-1425. 
39. Bafna S, Kaur S, Batra SK (2010) Membrane-bound mucins: the 
mechanistic basis for alterations in the growth and survival of cancer 
cells. Oncogene 29: 2893-2904. 
40. Carraway KL, Price-Schiavi SA, Komatsu M, Idris N, Perez A, et al. 
(2000) Multiple facets of sialomucin complex/MUC4, a membrane 
mucin and erbb2 ligand, in tumors and tissues (Y2K update). Front 
Biosci 5: D95-D107. 
41. Jepson S, Komatsu M, Haq B, Arango ME, Huang D, et al. (2002) 
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces 
specific phosphorylation of ErbB2 and enhances expression of 
p27(kip), but does not activate mitogen-activated kinase or protein 
kinaseB/Akt pathways. Oncogene 21: 7524-7532. 
42. Parry S, Silverman HS, McDermott K, Willis A, Hollingsworth MA, et 
al. (2001) Identification of MUC1 proteolytic cleavage sites in vivo. 
Biochem Biophys Res Commun 283: 715-720. 
43. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and 
control of the cell surface. Nat Rev Cancer 4: 45-60. 
44. Davis CW, Dickey BF (2008) Regulated airway goblet cell mucin 
secretion. Annu Rev Physiol 70: 487-512. 
 45 
45. McGuckin MA, Linden SK, Sutton P, Florin TH (2011) Mucin dynamics 
and enteric pathogens. Nat Rev Microbiol 9: 265-278. 
46. Specian RD, Neutra MR (1980) Mechanism of rapid mucus secretion in 
goblet cells stimulated by acetylcholine. J Cell Biol 85: 626-640. 
47. McCool DJ, Marcon MA, Forstner JF, Forstner GG (1990) The T84 
human colonic adenocarcinoma cell line produces mucin in culture 
and releases it in response to various secretagogues. Biochem J 267: 
491-500. 
48. McCool DJ, Forstner JF, Forstner GG (1995) Regulated and unregulated 
pathways for MUC2 mucin secretion in human colonic LS180 
adenocarcinoma cells are distinct. Biochem J 312 ( Pt 1): 125-133. 
49. Smirnova MG, Guo L, Birchall JP, Pearson JP (2003) LPS up-regulates 
mucin and cytokine mRNA expression and stimulates mucin and 
cytokine secretion in goblet cells. Cell Immunol 221: 42-49. 
50. Enss ML, Cornberg M, Wagner S, Gebert A, Henrichs M, et al. (2000) 
Proinflammatory cytokines trigger MUC gene expression and mucin 
release in the intestinal cancer cell line LS180. Inflamm Res 49: 162-
169. 
51. Kim KC, Lee BC, Pou S, Ciccolella D (2003) Effects of activation of 
polymorphonuclear leukocytes on airway goblet cell mucin release in 
a co-culture system. Inflamm Res 52: 258-262. 
52. Hollande E, Fanjul M, Claret S, Forgue-Lafitte ME, Bara J (1995) Effects 
of VIP on the regulation of mucin secretion in cultured human 
pancreatic cancer cells (Capan-1). In Vitro Cell Dev Biol Anim 31: 
227-233. 
53. Smirnova MG, Birchall JP, Pearson JP (2000) TNF-alpha in the 
regulation of MUC5AC secretion: some aspects of cytokine-induced 
mucin hypersecretion on the in vitro model. Cytokine 12: 1732-1736. 
54. Klinkspoor JH, Mok KS, Van Klinken BJ, Tytgat GN, Lee SP, et al. 
(1999) Mucin secretion by the human colon cell line LS174T is 
regulated by bile salts. Glycobiology 9: 13-19. 
55. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, et al. (1999) 
Neutrophil elastase increases MUC5AC mRNA and protein 
expression in respiratory epithelial cells. Am J Physiol 276: L835-
843. 
56. Jarry A, Vallette G, Branka JE, Laboisse C (1996) Direct secretory effect 
of interleukin-1 via type I receptors in human colonic mucous 
epithelial cells (HT29-C1.16E). Gut 38: 240-242. 
57. Kim KC, Park HR, Shin CY, Akiyama T, Ko KH (1996) Nucleotide-
induced mucin release from primary hamster tracheal surface 
epithelial cells involves the P2u purinoceptor. Eur Respir J 9: 1579. 
58. Choi J, Klinkspoor JH, Yoshida T, Lee SP (1999) Lipopolysaccharide 
from Escherichia coli stimulates mucin secretion by cultured dog 
gallbladder epithelial cells. Hepatology 29: 1352-1357. 
Mucus and mucins during gastrointestinal infections 
46 
59. Lencer WI, Reinhart FD, Neutra MR (1990) Interaction of cholera toxin 
with cloned human goblet cells in monolayer culture. Am J Physiol 
258: G96-102. 
60. Leitch GJ (1988) Cholera enterotoxin-induced mucus secretion and 
increase in the mucus blanket of the rabbit ileum in vivo. Infect 
Immun 56: 2871-2875. 
61. Steinberg SE, Banwell JG, Yardley JH, Keusch GT, Hendrix TR (1975) 
Comparison of secretory and histological effects of shigella and 
cholera enterotoxins in rabbit jejunum. Gastroenterology 68: 309-
317. 
62. Chadee K, Meerovitch E (1985) Entamoeba histolytica: early progressive 
pathology in the cecum of the gerbil (Meriones unguiculatus). Am J 
Trop Med Hyg 34: 283-291. 
63. Belley A, Keller K, Gottke M, Chadee K (1999) Intestinal mucins in 
colonization and host defense against pathogens. Am J Trop Med 
Hyg 60: 10-15. 
64. Berin MC, Sampson HA (2013) Mucosal immunology of food allergy. 
Curr Biol 23: R389-400. 
65. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, et al. (2007) MUC1 
oncoprotein activates the IkappaB kinase beta complex and 
constitutive NF-kappaB signalling. Nat Cell Biol 9: 1419-1427. 
66. Guang W, Ding H, Czinn SJ, Kim KC, Blanchard TG, et al. (2010) Muc1 
cell surface mucin attenuates epithelial inflammation in response to a 
common mucosal pathogen. J Biol Chem 285: 20547-20557. 
67. Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, et 
al. (1999) The B-cell system of human mucosae and exocrine glands. 
Immunol Rev 171: 45-87. 
68. Kang W, Rathinavelu S, Samuelson LC, Merchant JL (2005) Interferon 
gamma induction of gastric mucous neck cell hypertrophy. Lab 
Invest 85: 702-715. 
69. Gregorieff A, Stange DE, Kujala P, Begthel H, van den Born M, et al. 
(2009) The ets-domain transcription factor Spdef promotes 
maturation of goblet and paneth cells in the intestinal epithelium. 
Gastroenterology 137: 1333-1345 e1331-1333. 
70. Chen G, Korfhagen TR, Xu Y, Kitzmiller J, Wert SE, et al. (2009) 
SPDEF is required for mouse pulmonary goblet cell differentiation 
and regulates a network of genes associated with mucus production. J 
Clin Invest 119: 2914-2924. 
71. Marko CK, Menon BB, Chen G, Whitsett JA, Clevers H, et al. (2013) 
Spdef null mice lack conjunctival goblet cells and provide a model of 
dry eye. Am J Pathol 183: 35-48. 
72. Yu H, Li Q, Kolosov VP, Perelman JM, Zhou X (2010) Interleukin-13 
induces mucin 5AC production involving STAT6/SPDEF in human 
airway epithelial cells. Cell Commun Adhes 17: 83-92. 
 47 
73. Hasnain SZ, Thornton DJ, Grencis RK (2011) Changes in the mucosal 
barrier during acute and chronic Trichuris muris infection. Parasite 
Immunol 33: 45-55. 
74. Jarry A, Muzeau F, Laboisse C (1992) Cytokine effects in a human 
colonic goblet cell line. Cellular damage and its partial prevention by 
5 aminosalicylic acid. Dig Dis Sci 37: 1170-1178. 
75. Wang P, Zhang G, Qin X, Qiu Z, Li N, et al. (2011) Inhibition of 
allergen-induced airway remodeling by neonatal bacillus Calmette-
Guerin vaccination is associated with interferon-gamma-producing T 
cells but not regulatory T cells in mice. Ann Allergy Asthma 
Immunol 107: 163-170. 
76. Longphre M, Li D, Gallup M, Drori E, Ordonez CL, et al. (1999) 
Allergen-induced IL-9 directly stimulates mucin transcription in 
respiratory epithelial cells. J Clin Invest 104: 1375-1382. 
77. Plaisancie P, Barcelo A, Moro F, Claustre J, Chayvialle JA, et al. (1998) 
Effects of neurotransmitters, gut hormones, and inflammatory 
mediators on mucus discharge in rat colon. Am J Physiol 275: 
G1073-1084. 
78. Knight PA, Brown JK, Pemberton AD (2008) Innate immune response 
mechanisms in the intestinal epithelium: potential roles for mast cells 
and goblet cells in the expulsion of adult Trichinella spiralis. 
Parasitology 135: 655-670. 
79. Shekels LL, Anway RE, Lin J, Kennedy MW, Garside P, et al. (2001) 
Coordinated Muc2 and Muc3 mucin gene expression in Trichinella 
spiralis infection in wild-type and cytokine-deficient mice. Dig Dis 
Sci 46: 1757-1764. 
80. Niv Y, Koren R (2003) Modulation of mucin synthesis by gamma-
interferon in human colon adenocarcinoma cells. Digestion 67: 50-
55. 
81. Bergstrom KS, Kissoon-Singh V, Gibson DL, Ma C, Montero M, et al. 
(2010) Muc2 protects against lethal infectious colitis by 
disassociating pathogenic and commensal bacteria from the colonic 
mucosa. PLoS Pathog 6: e1000902. 
82. Hasnain SZ, Wang H, Ghia JE, Haq N, Deng Y, et al. (2010) Mucin gene 
deficiency in mice impairs host resistance to an enteric parasitic 
infection. Gastroenterology 138: 1763-1771. 
83. Linden SK, Sheng YH, Every AL, Miles KM, Skoog EC, et al. (2009) 
MUC1 limits Helicobacter pylori infection both by steric hindrance 
and by acting as a releasable decoy. PLoS Pathog 5: e1000617. 
84. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, et al. 
(2007) MUC1 cell surface mucin is a critical element of the mucosal 
barrier to infection. J Clin Invest 117: 2313-2324. 
85. Drake D, Montie TC (1988) Flagella, motility and invasive virulence of 
Pseudomonas aeruginosa. J Gen Microbiol 134: 43-52. 
Mucus and mucins during gastrointestinal infections 
48 
86. Ottemann KM, Lowenthal AC (2002) Helicobacter pylori uses motility 
for initial colonization and to attain robust infection. Infect Immun 
70: 1984-1990. 
87. Krukonis ES, DiRita VJ (2003) From motility to virulence: Sensing and 
responding to environmental signals in Vibrio cholerae. Curr Opin 
Microbiol 6: 186-190. 
88. Marchetti M, Sirard JC, Sansonetti P, Pringault E, Kerneis S (2004) 
Interaction of pathogenic bacteria with rabbit appendix M cells: 
bacterial motility is a key feature in vivo. Microbes Infect 6: 521-
528. 
89. Ramos HC, Rumbo M, Sirard JC (2004) Bacterial flagellins: mediators of 
pathogenicity and host immune responses in mucosa. Trends 
Microbiol 12: 509-517. 
90. Celli JP, Turner BS, Afdhal NH, Keates S, Ghiran I, et al. (2009) 
Helicobacter pylori moves through mucus by reducing mucin 
viscoelasticity. Proc Natl Acad Sci U S A 106: 14321-14326. 
91. Lidell ME, Moncada DM, Chadee K, Hansson GC (2006) Entamoeba 
histolytica cysteine proteases cleave the MUC2 mucin in its C-
terminal domain and dissolve the protective colonic mucus gel. Proc 
Natl Acad Sci U S A 103: 9298-9303. 
92. Ota H, Nakayama J, Momose M, Hayama M, Akamatsu T, et al. (1998) 
Helicobacter pylori infection produces reversible glycosylation 
changes to gastric mucins. Virchows Arch 433: 419-426. 
93. Binker MG, Binker-Cosen AA, Richards D, Oliver B, Cosen-Binker LI 
(2009) LPS-stimulated MUC5AC production involves Rac1-
dependent MMP-9 secretion and activation in NCI-H292 cells. 
Biochem Biophys Res Commun 386: 124-129. 
94. Li W, Yan F, Zhou H, Lin X, Wu Y, et al. (2013) P. aeruginosa 
lipopolysaccharide-induced MUC5AC and CLCA3 expression is 
partly through Duox1 in vitro and in vivo. PLoS One 8: e63945. 
95. Ben Mohamed F, Garcia-Verdugo I, Medina M, Balloy V, Chignard M, 
et al. (2012) A crucial role of Flagellin in the induction of airway 
mucus production by Pseudomonas aeruginosa. PLoS One 7: e39888. 
96. Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, et al. 
(2013) Macrolides inhibit Fusobacterium nucleatum-induced 
MUC5AC production in human airway epithelial cells. Antimicrob 
Agents Chemother 57: 1844-1849. 
97. Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, et al. (2008) 
MUC1 mucin is a negative regulator of toll-like receptor signaling. 
Am J Respir Cell Mol Biol 38: 263-268. 
98. Mitchell HM (1999) The epidemiology of Helicobacter pylori. Curr Top 
Microbiol Immunol 241: 11-30. 
99. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, et al. (1997) 
Helicobacter pylori infection and chronic gastric acid hyposecretion. 
Gastroenterology 113: 15-24. 
 49 
100. Konturek PC, Konturek SJ, Brzozowski T (2009) Helicobacter pylori 
infection in gastric cancerogenesis. J Physiol Pharmacol 60: 3-21. 
101. Malfertheiner P (2011) The intriguing relationship of Helicobacter 
pylori infection and acid secretion in peptic ulcer disease and gastric 
cancer. Dig Dis 29: 459-464. 
102. Wotherspoon AC, Diss TC, Pan LX, Schmid C, Kerr-Muir MG, et al. 
(1993) Primary low-grade B-cell lymphoma of the conjunctiva: a 
mucosa-associated lymphoid tissue type lymphoma. Histopathology 
23: 417-424. 
103. Wroblewski LE, Peek RM, Jr., Wilson KT (2010) Helicobacter pylori 
and gastric cancer: factors that modulate disease risk. Clin Microbiol 
Rev 23: 713-739. 
104. Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, et al. 
(2002) Age at acquisition of Helicobacter pylori infection: a follow-
up study from infancy to adulthood. Lancet 359: 931-935. 
105. Eaton KA, Brooks CL, Morgan DR, Krakowka S (1991) Essential role 
of urease in pathogenesis of gastritis induced by Helicobacter pylori 
in gnotobiotic piglets. Infect Immun 59: 2470-2475. 
106. Sachs G, Weeks DL, Wen Y, Marcus EA, Scott DR, et al. (2005) Acid 
acclimation by Helicobacter pylori. Physiology (Bethesda) 20: 429-
438. 
107. Celli JP, Turner BS, Afdhal NH, Ewoldt RH, McKinley GH, et al. 
(2007) Rheology of gastric mucin exhibits a pH-dependent sol-gel 
transition. Biomacromolecules 8: 1580-1586. 
108. Spohn G, Scarlato V (2001) Motility, Chemotaxis, and Flagella. In: 
Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: 
Physiology and Genetics. Washington (DC). 
109. Spagnolie SE, Liu B, Powers TR (2013) Locomotion of helical bodies in 
viscoelastic fluids: enhanced swimming at large helical amplitudes. 
Phys Rev Lett 111: 068101. 
110. Yamaguchi H, Osaki T, Taguchi H, Hanawa T, Yamamoto T, et al. 
(1996) Flow cytometric analysis of the heat shock protein 60 
expressed on the cell surface of Helicobacter pylori. J Med Microbiol 
45: 270-277. 
111. Peck B, Ortkamp M, Diehl KD, Hundt E, Knapp B (1999) Conservation, 
localization and expression of HopZ, a protein involved in adhesion 
of Helicobacter pylori. Nucleic Acids Res 27: 3325-3333. 
112. Odenbreit S, Till M, Hofreuter D, Faller G, Haas R (1999) Genetic and 
functional characterization of the alpAB gene locus essential for the 
adhesion of Helicobacter pylori to human gastric tissue. Mol 
Microbiol 31: 1537-1548. 
113. Dossumbekova A, Prinz C, Mages J, Lang R, Kusters JG, et al. (2006) 
Helicobacter pylori HopH (OipA) and bacterial pathogenicity: 
genetic and functional genomic analysis of hopH gene 
polymorphisms. J Infect Dis 194: 1346-1355. 
Mucus and mucins during gastrointestinal infections 
50 
114. Yamaoka Y (2008) Roles of Helicobacter pylori BabA in 
gastroduodenal pathogenesis. World J Gastroenterol 14: 4265-4272. 
115. Boren T, Falk P, Roth KA, Larson G, Normark S (1993) Attachment of 
Helicobacter pylori to human gastric epithelium mediated by blood 
group antigens. Science 262: 1892-1895. 
116. Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, et al. (2002) 
Helicobacter pylori SabA adhesin in persistent infection and chronic 
inflammation. Science 297: 573-578. 
117. Kwok T, Zabler D, Urman S, Rohde M, Hartig R, et al. (2007) 
Helicobacter exploits integrin for type IV secretion and kinase 
activation. Nature 449: 862-866. 
118. Linden SK, Wickstrom C, Lindell G, Gilshenan K, Carlstedt I (2008) 
Four modes of adhesion are used during Helicobacter pylori binding 
to human mucins in the oral and gastric niches. Helicobacter 13: 81-
93. 
119. Boquet P, Ricci V (2012) Intoxication strategy of Helicobacter pylori 
VacA toxin. Trends Microbiol 20: 165-174. 
120. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R (2003) 
Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte 
activation. Science 301: 1099-1102. 
121. Torres VJ, VanCompernolle SE, Sundrud MS, Unutmaz D, Cover TL 
(2007) Helicobacter pylori vacuolating cytotoxin inhibits activation-
induced proliferation of human T and B lymphocyte subsets. J 
Immunol 179: 5433-5440. 
122. Fischer W (2011) Assembly and molecular mode of action of the 
Helicobacter pylori Cag type IV secretion apparatus. FEBS J 278: 
1203-1212. 
123. Crabtree JE, Wyatt JI, Trejdosiewicz LK, Peichl P, Nichols PH, et al. 
(1994) Interleukin-8 expression in Helicobacter pylori infected, 
normal, and neoplastic gastroduodenal mucosa. J Clin Pathol 47: 61-
66. 
124. Jung HC, Kim JM, Song IS, Kim CY (1997) Helicobacter pylori induces 
an array of pro-inflammatory cytokines in human gastric epithelial 
cells: quantification of mRNA for interleukin-8, -1 alpha/beta, 
granulocyte-macrophage colony-stimulating factor, monocyte 
chemoattractant protein-1 and tumour necrosis factor-alpha. J 
Gastroenterol Hepatol 12: 473-480. 
125. Pellicano A, Sebkova L, Monteleone G, Guarnieri G, Imeneo M, et al. 
(2007) Interleukin-12 drives the Th1 signaling pathway in 
Helicobacter pylori-infected human gastric mucosa. Infect Immun 
75: 1738-1744. 
126. Karttunen R, Karttunen T, Ekre HP, MacDonald TT (1995) Interferon 
gamma and interleukin 4 secreting cells in the gastric antrum in 
Helicobacter pylori positive and negative gastritis. Gut 36: 341-345. 
 51 
127. Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, et al. 
(2000) Up-regulation of IL-17 is associated with bioactive IL-8 
expression in Helicobacter pylori-infected human gastric mucosa. J 
Immunol 165: 5332-5337. 
128. Linden S, Nordman H, Hedenbro J, Hurtig M, Boren T, et al. (2002) 
Strain- and blood group-dependent binding of Helicobacter pylori to 
human gastric MUC5AC glycoforms. Gastroenterology 123: 1923-
1930. 
129. Linden S, Boren T, Dubois A, Carlstedt I (2004) Rhesus monkey gastric 
mucins: oligomeric structure, glycoforms and Helicobacter pylori 
binding. Biochem J 379: 765-775. 
130. McGuckin MA, Every AL, Skene CD, Linden SK, Chionh YT, et al. 
(2007) Muc1 mucin limits both Helicobacter pylori colonization of 
the murine gastric mucosa and associated gastritis. Gastroenterology 
133: 1210-1218. 
131. Skoog EC, Sjoling A, Navabi N, Holgersson J, Lundin SB, et al. (2012) 
Human gastric mucins differently regulate Helicobacter pylori 
proliferation, gene expression and interactions with host cells. PLoS 
One 7: e36378. 
132. Marques T, David L, Reis C, Nogueira A (2005) Topographic 
expression of MUC5AC and MUC6 in the gastric mucosa infected 
by Helicobacter pylori and in associated diseases. Pathol Res Pract 
201: 665-672. 
133. Kang HM, Kim N, Park YS, Hwang JH, Kim JW, et al. (2008) Effects 
of Helicobacter pylori Infection on gastric mucin expression. J Clin 
Gastroenterol 42: 29-35. 
134. Byrd JC, Yan P, Sternberg L, Yunker CK, Scheiman JM, et al. (1997) 
Aberrant expression of gland-type gastric mucin in the surface 
epithelium of Helicobacter pylori-infected patients. Gastroenterology 
113: 455-464. 
135. Van den Brink GR, Tytgat KM, Van der Hulst RW, Van der Loos CM, 
Einerhand AW, et al. (2000) H pylori colocalises with MUC5AC in 
the human stomach. Gut 46: 601-607. 
136. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS (2000) 
Inhibition of gastric mucin synthesis by Helicobacter pylori. 
Gastroenterology 118: 1072-1079. 
137. Kocer B, Ulas M, Ustundag Y, Erdogan S, Karabeyoglu M, et al. (2004) 
A confirmatory report for the close interaction of Helicobacter pylori 
with gastric epithelial MUC5AC expression. J Clin Gastroenterol 38: 
496-502. 
138. Newton JL, Jordan N, Oliver L, Strugala V, Pearson J, et al. (1998) 
Helicobacter pylori in vivo causes structural changes in the adherent 
gastric mucus layer but barrier thickness is not compromised. Gut 43: 
470-475. 
Mucus and mucins during gastrointestinal infections 
52 
139. Henriksnas J, Phillipson M, Storm M, Engstrand L, Soleimani M, et al. 
(2006) Impaired mucus-bicarbonate barrier in Helicobacter pylori-
infected mice. Am J Physiol Gastrointest Liver Physiol 291: G396-
403. 
140. Hidaka E, Ota H, Hidaka H, Hayama M, Matsuzawa K, et al. (2001) 
Helicobacter pylori and two ultrastructurally distinct layers of gastric 
mucous cell mucins in the surface mucous gel layer. Gut 49: 474-
480. 
141. Kawakubo M, Ito Y, Okimura Y, Kobayashi M, Sakura K, et al. (2004) 
Natural antibiotic function of a human gastric mucin against 
Helicobacter pylori infection. Science 305: 1003-1006. 
142. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, et 
al. (1997) A standardized mouse model of Helicobacter pylori 
infection: introducing the Sydney strain. Gastroenterology 112: 
1386-1397. 
143. Takahashi S, Okabe S (1998) [Rodent models of Helicobacter pylori 
infection and their utility]. Nihon Yakurigaku Zasshi 111: 289-296. 
144. Mainil J (2013) Escherichia coli virulence factors. Vet Immunol 
Immunopathol 152: 2-12. 
145. Isidean SD, Riddle MS, Savarino SJ, Porter CK (2011) A systematic 
review of ETEC epidemiology focusing on colonization factor and 
toxin expression. Vaccine 29: 6167-6178. 
146. Gaastra W, Svennerholm AM (1996) Colonization factors of human 
enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 4: 444-
452. 
147. Taxt A, Aasland R, Sommerfelt H, Nataro J, Puntervoll P (2010) Heat-
stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine 
target. Infect Immun 78: 1824-1831. 
148. Kumar P, Luo Q, Vickers TJ, Sheikh A, Lewis WG, et al. (2013) EatA, 
an Immununogenic Protective Antigen of Enterotoxigenic 
Escherichia coli Degrades Intestinal Mucin. Infect Immun. 
149. Luo Q, Kumar P, Vickers T, Sheikh A, Lewis WG, et al. (2013) 
Enterotoxigenic Escherichia coli secrete a highly conserved mucin-
degrading metalloprotease to effectively engage intestinal epithelial 
cells. Infect Immun. 
150. Peng QL, Ren J, Yan XM, Huang X, Tang H, et al. (2007) The 
g.243A>G mutation in intron 17 of MUC4 is significantly associated 
with susceptibility/resistance to ETEC F4ab/ac infection in pigs. 
Anim Genet 38: 397-400. 
151. Zhang B, Ren J, Yan X, Huang X, Ji H, et al. (2008) Investigation of the 
porcine MUC13 gene: isolation, expression, polymorphisms and 
strong association with susceptibility to enterotoxigenic Escherichia 
coli F4ab/ac. Anim Genet 39: 258-266. 
152. Ji H, Ren J, Yan X, Huang X, Zhang B, et al. (2011) The porcine 
MUC20 gene: molecular characterization and its association with 
 53 
susceptibility to enterotoxigenic Escherichia coli F4ab/ac. Mol Biol 
Rep 38: 1593-1601. 
153. Zhou C, Liu Z, Jiang J, Yu Y, Zhang Q (2012) Differential gene 
expression profiling of porcine epithelial cells infected with three 
enterotoxigenic Escherichia coli strains. BMC Genomics 13: 330. 
154. Zhou C, Liu Z, Liu Y, Fu W, Ding X, et al. (2013) Gene silencing of 
porcine MUC13 and ITGB5: candidate genes towards Escherichia 
coli F4ac adhesion. PLoS One 8: e70303. 
155. Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, et al. (2010) 
Secretory IgA-mediated protection against V. cholerae and heat-
labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-
based vaccine. Proc Natl Acad Sci U S A 107: 8794-8799. 
156. Wenneras C, Svennerholm AM, Czerkinsky C (1994) Vaccine-specific 
T cells in human peripheral blood after oral immunization with an 
inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun 
62: 874-879. 
157. Leach S, Clements JD, Kaim J, Lundgren A (2012) The adjuvant double 
mutant Escherichia coli heat labile toxin enhances IL-17A production 
in human T cells specific for bacterial vaccine antigens. PLoS One 7: 
e51718. 
158. Byrd W, Mog SR, Cassels FJ (2003) Pathogenicity and immune 
response measured in mice following intranasal challenge with 
enterotoxigenic Escherichia coli strains H10407 and B7A. Infect 
Immun 71: 13-21. 
159. Nataro JP, Kaper JB (1998) Diarrheagenic Escherichia coli. Clin 
Microbiol Rev 11: 142-201. 
160. Garmendia J, Frankel G, Crepin VF (2005) Enteropathogenic and 
enterohemorrhagic Escherichia coli infections: translocation, 
translocation, translocation. Infect Immun 73: 2573-2585. 
161. Robins-Browne RM, Hartland EL (2002) Escherichia coli as a cause of 
diarrhea. J Gastroenterol Hepatol 17: 467-475. 
162. Navarro-Garcia F, Serapio-Palacios A, Ugalde-Silva P, Tapia-Pastrana 
G, Chavez-Duenas L (2013) Actin cytoskeleton manipulation by 
effector proteins secreted by diarrheagenic Escherichia coli 
pathotypes. Biomed Res Int 2013: 374395. 
163. Wong AR, Pearson JS, Bright MD, Munera D, Robinson KS, et al. 
(2011) Enteropathogenic and enterohaemorrhagic Escherichia coli: 
even more subversive elements. Mol Microbiol 80: 1420-1438. 
164. Deane JE, Abrusci P, Johnson S, Lea SM (2010) Timing is everything: 
the regulation of type III secretion. Cell Mol Life Sci 67: 1065-1075. 
165. Schauer DB, Zabel BA, Pedraza IF, O'Hara CM, Steigerwalt AG, et al. 
(1995) Genetic and biochemical characterization of Citrobacter 
rodentium sp. nov. J Clin Microbiol 33: 2064-2068. 
Mucus and mucins during gastrointestinal infections 
54 
166. Barthold SW, Coleman GL, Jacoby RO, Livestone EM, Jonas AM 
(1978) Transmissible murine colonic hyperplasia. Vet Pathol 15: 
223-236. 
167. Schauer DB, Falkow S (1993) Attaching and effacing locus of a 
Citrobacter freundii biotype that causes transmissible murine colonic 
hyperplasia. Infect Immun 61: 2486-2492. 
168. Schmidt MA (2010) LEEways: tales of EPEC, ATEC and EHEC. Cell 
Microbiol 12: 1544-1552. 
169. Khan MA, Bouzari S, Ma C, Rosenberger CM, Bergstrom KS, et al. 
(2008) Flagellin-dependent and -independent inflammatory responses 
following infection by enteropathogenic Escherichia coli and 
Citrobacter rodentium. Infect Immun 76: 1410-1422. 
170. Grys TE, Walters LL, Welch RA (2006) Characterization of the StcE 
protease activity of Escherichia coli O157:H7. J Bacteriol 188: 4646-
4653. 
171. Vallance BA, Deng W, Knodler LA, Finlay BB (2002) Mice lacking T 
and B lymphocytes develop transient colitis and crypt hyperplasia yet 
suffer impaired bacterial clearance during Citrobacter rodentium 
infection. Infect Immun 70: 2070-2081. 
172. Maaser C, Housley MP, Iimura M, Smith JR, Vallance BA, et al. (2004) 
Clearance of Citrobacter rodentium requires B cells but not secretory 
immunoglobulin A (IgA) or IgM antibodies. Infect Immun 72: 3315-
3324. 
173. Simmons CP, Clare S, Ghaem-Maghami M, Uren TK, Rankin J, et al. 
(2003) Central role for B lymphocytes and CD4+ T cells in immunity 
to infection by the attaching and effacing pathogen Citrobacter 
rodentium. Infect Immun 71: 5077-5086. 
174. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D (2007) 
TLR signaling mediated by MyD88 is required for a protective innate 
immune response by neutrophils to Citrobacter rodentium. J 
Immunol 179: 566-577. 
175. Wei OL, Hilliard A, Kalman D, Sherman M (2005) Mast cells limit 
systemic bacterial dissemination but not colitis in response to 
Citrobacter rodentium. Infect Immun 73: 1978-1985. 
176. Simmons CP, Goncalves NS, Ghaem-Maghami M, Bajaj-Elliott M, 
Clare S, et al. (2002) Impaired resistance and enhanced pathology 
during infection with a noninvasive, attaching-effacing enteric 
bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or 
IFN-gamma. J Immunol 168: 1804-1812. 
177. Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VS, 
Mandelboim O, et al. (2009) The natural cytotoxicity receptor 
NKp46 is dispensable for IL-22-mediated innate intestinal immune 
defense against Citrobacter rodentium. J Immunol 183: 6579-6587. 
178. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, et al. (2009) 
Differential roles of interleukin-17A and -17F in host defense against 
 55 
mucoepithelial bacterial infection and allergic responses. Immunity 
30: 108-119. 
179. Shiomi H, Masuda A, Nishiumi S, Nishida M, Takagawa T, et al. (2010) 
Gamma interferon produced by antigen-specific CD4+ T cells 
regulates the mucosal immune responses to Citrobacter rodentium 
infection. Infect Immun 78: 2653-2666. 
180. Allan-Wojtas P, Farnworth ER, Modler HW, Carbyn S (1997) A 
solvent-based fixative for electron microscopy to improve retention 
and visualization of the intestinal mucus blanket for probiotics 
studies. Microsc Res Tech 36: 390-399. 
181. Lievin-Le Moal V, Servin AL (2006) The front line of enteric host 
defense against unwelcome intrusion of harmful microorganisms: 
mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 
19: 315-337. 
182. Dharmani P, Srivastava V, Kissoon-Singh V, Chadee K (2009) Role of 
intestinal mucins in innate host defense mechanisms against 
pathogens. J Innate Immun 1: 123-135. 
183. Andrianifahanana M, Moniaux N, Batra SK (2006) Regulation of mucin 
expression: mechanistic aspects and implications for cancer and 
inflammatory diseases. Biochim Biophys Acta 1765: 189-222. 
184. Lee MK, Yoo JW, Lin H, Kim YS, Kim DD, et al. (2005) Air-liquid 
interface culture of serially passaged human nasal epithelial cell 
monolayer for in vitro drug transport studies. Drug Deliv 12: 305-
311. 
185. Yang JJ, Ueda H, Kim K, Lee VH (2000) Meeting future challenges in 
topical ocular drug delivery: development of an air-interfaced 
primary culture of rabbit conjunctival epithelial cells on a permeable 
support for drug transport studies. J Control Release 65: 1-11. 
186. Linden SK, Driessen KM, McGuckin MA (2007) Improved in vitro 
model systems for gastrointestinal infection by choice of cell line, 
pH, microaerobic conditions, and optimization of culture conditions. 
Helicobacter 12: 341-353. 
187. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, et al. 
(2005) Notch/gamma-secretase inhibition turns proliferative cells in 
intestinal crypts and adenomas into goblet cells. Nature 435: 959-
963. 
188. Moncada DM, Kammanadiminti SJ, Chadee K (2003) Mucin and Toll-
like receptors in host defense against intestinal parasites. Trends 
Parasitol 19: 305-311. 
189. Kim YS, Ho SB (2010) Intestinal goblet cells and mucins in health and 
disease: recent insights and progress. Curr Gastroenterol Rep 12: 
319-330. 
190. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, et al. (2008) 
Interleukin-22 mediates early host defense against attaching and 
effacing bacterial pathogens. Nat Med 14: 282-289. 
Mucus and mucins during gastrointestinal infections 
56 
191. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, et al. (1999) 
Altered tight junction structure contributes to the impaired epithelial 
barrier function in ulcerative colitis. Gastroenterology 116: 301-309. 
192. Resta-Lenert S, Barrett KE (2003) Live probiotics protect intestinal 
epithelial cells from the effects of infection with enteroinvasive 
Escherichia coli (EIEC). Gut 52: 988-997. 
193. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR 
(2007) The effect of nicotine in vitro on the integrity of tight 
junctions in Caco-2 cell monolayers. Food Chem Toxicol 45: 1593-
1598. 
194. Kalinowski S, Figaszewski Z (1992) A new system for bilayer lipid 
membrane capacitance measurements: method, apparatus and 
applications. Biochim Biophys Acta 1112: 57-66. 
195. Bertrand CA, Durand DM, Saidel GM, Laboisse C, Hopfer U (1998) 
System for dynamic measurements of membrane capacitance in 
intact epithelial monolayers. Biophys J 75: 2743-2756. 
196. Bertrand CA, Laboisse CL, Hopfer U (1999) Purinergic and cholinergic 
agonists induce exocytosis from the same granule pool in HT29-
Cl.16E monolayers. Am J Physiol 276: C907-914. 
197. Conlin VS, Wu X, Nguyen C, Dai C, Vallance BA, et al. (2009) 
Vasoactive intestinal peptide ameliorates intestinal barrier disruption 
associated with Citrobacter rodentium-induced colitis. Am J Physiol 
Gastrointest Liver Physiol 297: G735-750. 
198. Halm DR, Halm ST (2000) Secretagogue response of goblet cells and 
columnar cells in human colonic crypts (vol 277, pg C501, 1999). 
American Journal of Physiology-Cell Physiology 278: C212-C233. 
199. Roumagnac I, Laboisse C (1987) A mucus-secreting human colonic 
epithelial cell line responsive to cholinergic stimulation. Biol Cell 61: 
65-68. 
200. Tornoe CW, Christensen C, Meldal M (2002) Peptidotriazoles on solid 
phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-
dipolar cycloadditions of terminal alkynes to azides. J Org Chem 67: 
3057-3064. 
201. Laughlin ST, Bertozzi CR (2009) Imaging the glycome. Proc Natl Acad 
Sci U S A 106: 12-17. 
202. Johansson ME (2012) Fast renewal of the distal colonic mucus layers by 
the surface goblet cells as measured by in vivo labeling of mucin 
glycoproteins. PLoS One 7: e41009. 
203. Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR (2005) 
Helicobacter pylori CagA induces a transition from polarized to 
invasive phenotypes in MDCK cells. Proc Natl Acad Sci U S A 102: 
16339-16344. 
204. Hershberg RM, Cho DH, Youakim A, Bradley MB, Lee JS, et al. (1998) 
Highly polarized HLA class II antigen processing and presentation 
by human intestinal epithelial cells. J Clin Invest 102: 792-803. 
 57 
205. Alemka A, Corcionivoschi N, Bourke B (2012) Defense and 
Adaptation: The Complex Inter-Relationship between Campylobacter 
jejuni and Mucus. Front Cell Infect Microbiol 2: 15. 
206. Johansson ME, Thomsson KA, Hansson GC (2009) Proteomic analyses 
of the two mucus layers of the colon barrier reveal that their main 
component, the Muc2 mucin, is strongly bound to the Fcgbp protein. 
J Proteome Res 8: 3549-3557. 
207. Hasnain SZ, Evans CM, Roy M, Gallagher AL, Kindrachuk KN, et al. 
(2011) Muc5ac: a critical component mediating the rejection of 
enteric nematodes. J Exp Med 208: 893-900. 
208. Patel KK, Miyoshi H, Beatty WL, Head RD, Malvin NP, et al. (2013) 
Autophagy proteins control goblet cell function by potentiating 
reactive oxygen species production. EMBO J 32: 3130-3144. 
209. Pelaseyed T, Gustafsson JK, Gustafsson IJ, Ermund A, Hansson GC 
(2013) Carbachol-induced MUC17 endocytosis is concomitant with 
NHE3 internalization and CFTR membrane recruitment in 
enterocytes. Am J Physiol Cell Physiol 305: C457-467. 
210. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, et al. 
(2014) Western diet induces dysbiosis with increased E coli in 
CEABAC10 mice, alters host barrier function favouring AIEC 
colonisation. Gut 63: 116-124. 
211. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K (1997) Induction 
of airway mucus production By T helper 2 (Th2) cells: a critical role 
for interleukin 4 in cell recruitment but not mucus production. J Exp 
Med 186: 1737-1747. 
212. Cohn L, Homer RJ, Niu N, Bottomly K (1999) T helper 1 cells and 
interferon gamma regulate allergic airway inflammation and mucus 
production. J Exp Med 190: 1309-1318. 
213. Jarry A, Merlin D, Velcich A, Hopfer U, Augenlicht LH, et al. (1994) 
Interferon-gamma modulates cAMP-induced mucin exocytosis 
without affecting mucin gene expression in a human colonic goblet 
cell line. Eur J Pharmacol 267: 95-103. 
214. Song JS, Kang CM, Yoo MB, Kim SJ, Yoon HK, et al. (2007) Nitric 
oxide induces MUC5AC mucin in respiratory epithelial cells through 
PKC and ERK dependent pathways. Respir Res 8: 28. 
215. Micots I, Augeron C, Laboisse CL, Muzeau F, Megraud F (1993) Mucin 
exocytosis: a major target for Helicobacter pylori. J Clin Pathol 46: 
241-245. 
216. Rodriguez-Pineiro AM, Bergstrom JH, Ermund A, Gustafsson JK, 
Schutte A, et al. (2013) Studies of mucus in mouse stomach, small 
intestine, and colon. II. Gastrointestinal mucus proteome reveals 
Muc2 and Muc5ac accompanied by a set of core proteins. Am J 
Physiol Gastrointest Liver Physiol 305: G348-356. 
217. Johansson MEV (2009) The MUC2 mucin - A network in the intestinal 
protective mucus. Thesis Title. 
Mucus and mucins during gastrointestinal infections 
58 
 
 
